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AN EXAMINATION OF THE RELATIONSHIP OF ABO BLOOD GROUP AND LIFESPAN
IN A HOSPITALIZED POPULATION IN THE SOUTHEASTERN UNITED STATES
By Tara Cothran Moon, Ph.D.
A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor of
Philosophy at Virginia Commonwealth University.
Virginia Commonwealth University, 2014.
Major Director: Teresa Nadder, PhD, MLS(ASCP)CM, Chairman and Associate Professor,
Department of Clinical Laboratory Sciences

The clinical significance of ABO blood group is evident and universally accepted with
regards to blood transfusion and pregnancy; however, the importance of ABO blood group as it
relates to other diseases or disorders and overall mortality is not fully understood by the
scientific community. Many studies have suggested associations between blood groups and
disease, but consensus has not been reached regarding overall survival or longevity. This
epidemiological, retrospective review of ABO blood group and age at the time of death in a
hospitalized population in the Southeastern United States is the first multi-site study to examine
this relationship.
The study population was 56% male, 63.4% White, 31.0% Black and 2.1% Hispanic.
Over half (61.1%) of the population had been transfused with red blood cells within one year of
death. Overall, group O (46.6%) was the most prevalent ABO blood group, followed by group

A (36.8%), Group B (12.9%) and group AB (3.7%). The population exhibited differences in the
frequencies of ABO blood groups across the races, with the Hispanic population having the
highest prevalence of group O (71.2%) and the Black and Asian populations having higher
frequencies of group B (22.2% and 23.1% respectively) when compared to the overall population
distribution. Lifespan ranged from 0 to 110 with a mean age at death of 58.7 years. While some
differences in the mean age at death were noted across ABO blood groups, the main effect of
ABO blood group on lifespan did not reach statistical significance when controlling for race,
gender and history of red blood cell transfusion. These results contradict other studies that found
an association between a particular ABO blood group and lifespan. Future work should consider
including cause of death or primary disease as potential confounders and targeting expanded
populations over a wider geographic area to increase generalizability and racial diversity.

Chapter One: Introduction

Prior to the discovery of the ABO blood groups, high rates of mortality resulted from
using animal and human blood sources for transfusion due to lack of knowledge of the
differences in blood composition observed between animals and humans and within the human
population (Giangrande, 2000). Since the discovery of the ABO blood groups in 1900
(Landsteiner, 1900), humans and many other primates can be typed for ABO blood group based
on the presence or absence of surface antigens on the red blood cells (RBC). The four human
ABO groups, A, B, AB, and O, are based on the inheritance of genes on chromosome 9. A
person’s ABO phenotype does not change as a result of environmental influences during his or
her life except in cases of bone marrow transplantation or certain disease states.
Previous research has revealed associations between ABO blood groups and disease
(Albert, 1996; Hein, Suadicani, & Gyntelberg, 1998; O'Donnell & Laffan, 2001; Suadicani,
Hein, & Gyntelberg, 2007). Some of these associations include malignancy, thrombosis, peptic
ulcers, bleeding and infectious diseases (Garratty, 2000). Although ABO blood group is
determined by inheritance, natural selection may have influenced the current frequencies of ABO
types among populations based on susceptibility to particular diseases or disorders (Aird,
Bentall, & Roberts, 1953; Cheng et al., 2005; Glass et al., 1985; Gonzalez Ordonez, Medina
Rodriguez, Martin, Alvarez, & Coto, 1999; Hutson, Atmar, Graham, & Estes, 2002; Marinaccio
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et al., 1995; Shimazu, Shimaoka, Sugimoto, Taenaka, & Hasegawa, 2000). This project will
investigate the relationship between ABO blood groups and length of life. As an introduction,
the process of the discovery of the ABO blood group system, the chemical and molecular
structure of the antigens, the inheritance of the genes, as well as the geographical and
racial/ethnic distribution of the ABO phenotypes will be presented.
Discovery of ABO Blood Groups
Three blood groups (A, B and O) were discovered in 1900 by Landsteiner. He tested
blood samples from himself and several colleagues by combining serum specimens with a
suspension of RBCs from each person. By observing agglutination in some mixtures but not in
others, he was able to classify the blood samples into three groups. Two years later, indications
of a fourth group (AB) were found by two of Landsteiner’s students (Decastello & Sturli, 1902).
Consequently, humans can be divided into four ABO groups according to the reactions with
which their RBCs exhibit with normal human sera. These serological reactions depend on the
presence or absence of A and B substances on the surface of the RBC, the active parts of which
are polysaccharide in nature (Roback, Grossman, Harris, & Hillyer, 2011). In serological terms,
the A and B substances are described as antigens or agglutinins. Group A RBCs carry only the
A antigen, B cells only the B antigen, AB cells carry both, and O cells carry neither (Table 1).
The antigens of the ABO blood group remain the most well-known and medically
important group of red cell antigens. These antigens are defined by carbohydrate epitopes on
glycoproteins and glycolipids located on the extracellular surface of the RBC membranes and in
other tissues, body fluids and organs (Oriol et al., 1981; Szulman, 1960; Triadou, Audran,
Rousset, Zweibaum, & Oriol, 1983; Trickett, Evans, MacIver, Smith, & Slapak, 1983). An ABO
antigen is identified by a series of carbohydrates attached to a lipid or protein component on the
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Table 1.
Antigens and Antibodies Found in the ABO Blood Groups

Blood Group

Antigens on the surface of RBCs

Antibodies in the plasma or serum

O

neither A nor B

Anti-A; Anti-B; Anti-A,B

A

A

Anti-B

B

B

Anti-A

AB

A, B

none

RBC membrane. These antigens are produced by a series of reactions in which enzymes
catalyze the transfer of sugar units. A person's genotype determines the type of enzymes present,
and therefore, the type of antigens that are on the RBCs. ABO blood types are inherited through
genes on chromosome 9 (Lewis, Kaita, Giblett, & Anderson, 1978). Although they can be
detected on the RBCs of five to six-week old embryos, A and B antigens are not fully developed
at birth, presumably because the branching oligosaccharide structures develop gradually. By two
to four years of age, A and B antigen expression is fully developed and remains fairly constant
throughout life. A human serum contains either, both or neither of the corresponding antibodies
or hemagglutinins, anti-A and anti-B. Landsteiner concluded from his experiments that human
plasma contains A and B antibodies when the corresponding antigen(s) is/are absent from the
host red cells (Table 1). ABO antibodies are present in human sera after the first few months of
life (Roback, Grossman, Harris, & Hillyer, 2011). Even in 2014, over 100 years after
Landsteiner’s discovery (1900), human blood is typed by the antigens on the surface of RBCs for
certain medical indications.
The serological activity of anti-A and anti-B forms the basis of ABO testing, which uses
known sera containing anti-A and anti-B and known A and B cells as reagents to test blood of an
3

unknown blood group. Anti-A in serum can attach to the A antigen on A or AB cells and cause
agglutination. Anti-B behaves similarly with B or AB cells. The ABO blood group system
remains most significant for transfusion practice since it is the only system for which the
reciprocal (or antithetical) antibodies are consistently and predictably present in the sera of most
people who have had no exposure to human red cells (Roback, Grossman, Harris, & Hillyer,
2011).
Structure and Function of ABO Antigens
Establishing the structure of the molecules carrying blood group antigens was built on the
base of the serologic knowledge discovered by Landsteiner (1900) and Decastello and Sturli
(1902). Though the ABO antigens are also distributed throughout the body in tissues, fluids and
organs (Oriol et al., 1981; Szulman, 1960; Triadou et al., 1983; Trickett et al., 1983), they
contribute to the architecture of the RBC membrane and have a clear role in adverse events such
as hemolytic transfusion reactions, hemolytic disease of the newborn, autoimmune hemolytic
anemia, graft rejection and spontaneous abortion. Although the ABO antigens are surface
markers on the external surface of the RBC membrane, their function may not be related directly
to the RBC. It is possible that we have labeled these antigens as “blood” groups because they are
defined serologically by red cells agglutinating with their corresponding antibody and because of
the known problems associated with blood transfusion and ABO incompatibility. However,
compatibility may not be their sole function. For example, research has shown that many gram
negative organisms (such as E. coli) have chemical moieties on their membranes resembling the
A and B antigens; and this is the stimulus for anti-A and anti-B production by human infants (G.
F. Springer, Williamson, & Brandes, 1961). Individuals lacking the A or B antigen make either
anti-B or anti-A when exposed to the environmental bacteria that are structurally similar to the A
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and B antigen (Garratty, 2005). Therefore, the anti-A and anti-B produced cross-react with red
blood cells expressing the corresponding antigen. The biological qualities assigned to these RBC
membrane structures are based on observed physiological alteration in RBCs that lack the
component, the documentation of similarities in the protein sequence (predicted from the gene’s
nucleotide sequence) to proteins of known function, and by inference using homologues already
identified in other cells.
Molecular structure. The genetics of the ABO blood group system was first described
in by Bernstein 1924 (as cited in Hosoi, 2008) as consisting of a set of three allelic genes, A, B
and O, at a single genetic locus. In 1976, the chromosomal assignment of the ABO locus was
mapped to the region 9q34.2 at the distal end of the long arm of chromosome 9 (Ferguson-Smith,
Aitken, Turleau, & de Grouchy, 1976). In 1990, Yamamoto and colleagues described the
molecular genetic basis of the ABO blood group system. The genes direct the occurrence and
location of A and B antigens; however, the products of the genes are not the antigens themselves,
but the enzymes (glycotransferases) that contribute to the production of the A and B antigens
(Yamamoto, Clausen, White, Marken, & Hakomori, 1990). The genes that direct A and B
antigen development are at three separate loci: ABO, Hh, and Se. Three common alleles (A, B
and O) are located at the ABO locus on chromosome 9 at 9q34.1-q34.2 (Zelinski, 1995), and the
genes at the other two loci, Hh and Se, are closely linked on chromosome 19 (Larsen, Ernst,
Nair, & Lowe, 1990). Hh and Se loci each have two recognizable alleles, one of which has no
demonstrable product and is considered an amorph. The active allele at the H locus, H, produces
a glycosyltransferase that acts at the cellular level to form the antigen on which A or B is built.
The amorph, h, is very rare with a prevalence of 0.004 percent (Das et al., 2001).

The Se gene

is responsible for the expression of H (and indirectly responsible for the expression of A and B)
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on the glycoproteins in epithelial secretions such as saliva. Secretors inherit the Se gene; and
their secreted glycoproteins express H, which can be converted to A and/or B antigen if the A
and/or B gene is/are also present. The amorph is called se.
The H locus encodes a fucosyltransferase that produces the H antigen on RBCs, which is
an essential precursor to the ABO blood group antigens. The A gene, encodes a glycotransferase
that bonds α-N-acetylgalactosamine to the D-galactose end of the H antigen and produces the A
antigen. The B gene similarly determines the presence of the B antigen by encoding a
glycotransferase that joins α-D-galactose to the D-galactose terminal sugar of the H antigen,
creating the B antigen. The O gene does not produce a functional protein; and in the
heterozygote with an A or B gene, has little influence on the expression the A or B antigen.
Thus, phenotypically, the O gene is recessive, and the A and B genes are codominant (Table 2).
Table 2.
Genotypes of the ABO Blood Groups
Group

Possible Genotypes

O

OO

A

AA, AO

B

BB, BO

AB

AB

A and B genes differ from one another by seven single-base substitutions, which result in
four possible amino acid substitutions (at positions 176, 235, 266 and 268) in the protein
sequence of the A and B transferases (Yamamoto & Hakomori, 1990). All variant A and B
phenotypes, which have a weaker expression of the A and B phenotypes (subgroups), have been
shown to be mutations of the A or B gene, resulting in less effective transferase production
6

(Ogasawara et al., 1996). Multiple polymorphisms have been shown in the noncoding regions of
genomic sequences of the ABO alleles (Seltsam, Hallensleben, Kollmann, & Blasczyk, 2003),
and these sequence variations can affect A and B antigen expression resulting in weak ABO
phenotypes (Seltsam et al., 2003). A single base deletion in the O allele shifts the codon reading
frame and is responsible for the loss of activity of the A glycotransferase (Yamamoto et al.,
1990).
Chemical structure. Because the A and B antigens are derived from a common
precursor, the H antigen, the nature of the H antigen is relevant to any discussion of the chemical
structure of the ABO blood group antigens. The H antigen is composed of the carbohydrate
sequence β-D-galactose, β-D-N-acetylglucosamine, β-D-galactose and 2-linked, α-L-fucose
linked to bands 3 and 4.5 proteins (Lowe, 1994). The H antigens are expressed as fucosecontaining glycan units, residing on the glycoproteins or glycolipids of RBC membranes or on
mucin glycoproteins in secretions (Lowe, 1994). These fucosylated glycans are the direct
substrates for the glycosyltransferases that give rise to the epitopes for the A, B and Lewis blood
group antigens. Therefore, group O RBCs have the greatest number of H antigenic structures of
the ABO blood groups.
The H antigen was first described by Morgan and Watkins (1969). The basic substance
from which all the ABO blood group antigens are built is chemically similar to the capsular
antigen of pneumococcus type XIV (Mourant, Kopec, & Domaniewska-Sobczak, 1976). In all
but a very few persons, an enzyme (the product of the H gene), causes a molecule of 1-fucose to
be added to the number 2 carbon of the terminal galactose of type 2 oligosaccharide chains,
giving rise to the H antigen (Morgan & Watkins, 1969; Morgan, 1970). This is further modified
by the A and B genes of the ABO system, which give rise to a further series of transforming
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enzymes, glycosyltransferases (Lowe, 1994). The O gene does not encode a functional enzyme.
The glucosyltransferases add individual sugars sequentially to sites on oligosaccharides
conferring ABO specificity.
Oligosaccharides are chains of sugars that can be attached to either protein
(glycoprotein), sphingolipid (glycosphingolipid) or lipid (glycolipid) carrier molecules. When
attached to proteins, oligosaccharides are linked either to the amide nitrogen of asparagine via an
N-acetylglucosamine or to the hydroxyl oxygen or serine or threonine via an Nacetylgalactosamine (Lowe, 1994). Glycoproteins are associated with the membranes of RBCs
and other cells. The body’s serous and mucous secretions contain soluble glycoproteins with
blood group antigen activity. In glycosphingolipids, structurally similar oligosaccharides are
attached via glucose to ceramide residues. Glycosphingolipids form part of the membranes of
RBCs, most endothelial cells and some epithelial cells (Oriol et al., 1981; Triadou et al., 1983;
Trickett et al., 1983).
A and B glycosyltransferases add specific sugars to oligosaccharide chains that have been
converted to H by the fucosyltransferase produced by the H gene. The A gene encodes alpha1,3N-acetylgalactosaminyltransferase and the B gene codes alpha1,3-galactosyltransferase (National
Center for Biotechnology Information, 2008). The O gene is known as an amorph because any
product to which it may give rise has no detectable effect on the H antigen. The A gene,
however, causes the addition of N-acetylgalactosamine, converting H antigen to A antigen. The
B gene causes galactose to be added to the H structure, giving rise similarly to the B antigen
(Lowe, 1994).
A, B and H antigens are constructed on oligosaccharide chains of four different types (1
to 4) which differ in the linkage of the terminal β-D-galactose to N-acetylglucosamine and in the
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characteristics of the carbohydrate chain (Lowe, 1994). The most abundant forms are type 1 and
type 2. In type 1 chains, the number 1 carbon of galactose is linked to the number 3 carbon of Nacetylglucosamine; in type 2 chains, the number 4 carbon of N-acetylglucosamine is the acceptor
for β-D-galactose. A, B and H antigens on the RBC surface are formed on type 2 chains present
in highly branched oligosaccharides attached to integral proteins of the RBC membrane, notably
bands 3 and 4.5, and on type 2 oligosaccharides bound to glycolipids (Lowe, 1994).
The transferase produced by the H gene adds fucose to the number 2 carbon on the
terminal galactose of type 1 and type 2 chains. The A and B gene transferases can attach their
immunodominant sugars to the number 3 sugar of the same galactose only if fucose is already
attached, i.e., if the core chain has been converted to H. Attachment of the sugar that defines the
A or B antigen diminishes the serological detection of H antigen in a reciprocal manner; the
expression of A or B and of H are inversely proportional (Lowe, 1994).
Environmental and Geographic Factors
Antigens of the ABO blood group system have been known since 1900, yet their
biological meaning is still largely obscure. The frequencies of ABO blood group phenotypes are
not equal and it has been suggested that polymorphic genes provide intraspecies diversity which
allows coping with diverse and rapidly evolving pathogens (Marionneau et al., 2001). Based on
available knowledge about the genes involved in the blood group antigens’ biosynthesis and
about their tissue distribution in humans, one could postulate about the selective forces that may
maintain or propagate these antigens. For example, some E.coli have ABO-like antigens on their
cell walls (Andersson, Carlin, Leontein, Lindquist, & Slettengren, 1989; G. F. Springer,
Williamson, & Brandes, 1961), and H antigen is chemically similar to the capsular antigen of
pneumococcus type XIV (Mourant et al., 1976). These similarities in antigen makeup could
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confer some resistance in individuals who manufacture the corresponding antibodies, and
increase the susceptibility of people whose blood group matches the antigens (Vogel,
Pettenkofer, & Helmbold, 1960). Therefore, the inference is that ABO prevalence is affected by
natural selection.
Because environments are dynamic, it may be that a gene or trait that hindered survival
and reproduction in the past, might aid in survival and reproduction today. In this way, natural
selection and adaptation work to adjust the prevalence of traits so that they are suited for a
particular environment. Changes brought about by man, creating environments never before
known could influence these tendencies. In order to examine the length of life of those with
differing ABO blood groups, it is necessary to consider the distribution of the ABO blood groups
and causes for the prevalence of certain blood groups among populations.
ABO Blood Groups and Disease
Beginning with Landsteiner’s discovery (1900), our understanding of the ABO blood
group system grew, the world of blood transfusion became safer, and scientists were able to
study one of the first human characteristics proven to be inherited. The ABO blood group
antigens also appear to have been important throughout our evolution because the frequencies of
different ABO blood types vary among different populations (Cavalli-Sforza, Menozzi, &
Piazza, 1994), suggesting that a particular blood type conferred a selection advantage. Research
has shown that specific ABO blood types are thought to be linked with increased or decreased
susceptibility to particular diseases (Albert, 1996; Cheng et al., 2005; Hein et al., 1998;
Kalayanarooj et al., 2007; Shimazu et al., 2000). For example, individuals of blood group O are
at a somewhat higher risk of contracting some infectious diseases, such as cholera (Albert, 1996;
Glass et al., 1985; Levine et al., 1979). People of blood group A are at a higher risk for some
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malignancies (Aird et al., 1953; Lee et al., 1990). Research suggests that group O is more
appealing to mosquitoes, which is a significant factor in contracting malaria. These findings
suggest that the ABO blood group antigens could have a physiological role previously unknown.
Although the biological role of ABO antigens is uncertain, it has been suggested that the
polymorphic genes of the ABO blood group provide the diversity needed to survive changing
environmental conditions and evolving pathogens (Marionneau et al., 2001). There have been
many research endeavors regarding the associations of ABO blood groups with specific diseases,
but fewer have examined an association with ABO blood groups and overall survival or lifespan.
A study of centenarians (persons over 100 years old) in Tokyo demonstrated a higher frequency
of group B in centenarians than in controls, suggesting that group B might be associated with
exceptional longevity (Shimizu et al., 2004). In contrast, a United States study of patients who
died in a tertiary care hospital found that the percentage of group B patients declined with age
(Brecher & Hay, 2011), suggesting that group B is not a marker for longevity, but may actually
be a marker for earlier death. Further contradiction was found in a Sicilian population in which
the authors concluded that the frequencies of ABO blood groups in centenarians and controls did
not differ significantly (Vasto et al., 2011). These disparate conclusions concerning a
relationship among ABO blood groups and longevity add support to the need for larger, more
comprehensive studies to address this question.
A variety of medical research has been concerned with epidemiological studies related to
ABO blood groups and associated mortality, diseases and disorders. However, only the
hemagglutination problems of incompatible ABO blood type in transfusion and compatibility
have been accepted by the scientific community as clinically significant. There remains a lack of
consensus about the relationship of ABO blood group with diseases, disorders and lifespan.
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This project will look at the significance of ABO blood groups by examining the relationship of
ABO blood group, transfusion and length of life in a Southeastern United States population.
Findings could provide evidence for a physiologic function of the structure of ABO blood group
antigens. The first step will be to clarify whether or not there is a relationship between ABO
blood group and lifespan.
Significance
The ABO blood group antigens are of prime importance in transfusion medicine. These
antigens are the most immunogenic of all the blood group antigens, and there are some
undeniable associations of blood groups with adverse events. Antibodies to blood group
antigens can cause hemolytic transfusion reactions, hemolytic disease of the newborn,
autoimmune hemolytic anemia, graft rejection, and spontaneous abortion. Despite their known
clinical importance in compatibility, the physiological functions of ABO blood group antigens
remain unknown. Numerous associations have been made between particular ABO phenotypes
and an increased susceptibility to disease (Aird et al., 1953; Albert, 1996; Hein et al., 1998; Lee
et al., 1990; O'Donnell & Laffan, 2001; Suadicani et al., 2007). These studies provide increasing
evidence that blood groups may play a biological role, though the salience of this issue persists.
The distribution of the four ABO blood groups, A, B, AB, and O, varies in populations
throughout the world (Cavalli-Sforza et al., 1994). Prevalence of the blood groups is determined
by the frequency of the three alleles at the ABO locus in different populations. Worldwide,
group O is the most common, followed by group A, then group B with group AB as the least
common (Cavalli-Sforza et al., 1994). Similar frequencies were found in a United States
population (Garratty, Glynn, & McEntire, 2004). As part of the Retrovirus Epidemiology Donor
Study, Garratty, Glynn and McEntire (2004) collected data on allogeneic and autologous blood
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donors over a 10-year period (1991-2000) and reported ABO/Rh(D) phenotype frequencies for
the major racial/ethnic groups in the United States. Their study resulted in the largest and most
diverse United States sample to date with a sample size of over 3 million. These authors found
that the highest percentage of group O was in the Hispanic (56.5%), North American Indian
(54.6%) and Black non-Hispanic (50.2%) populations. Among all races/ethnicities, group O was
the most prevalent and group AB the least prevalent. The prevalence of group B was highest in
the Asian population (25.4%). The ABO phenotype differences between racial/ethnic groups
were found to all be statistically significant, (p < 0.0001) (Garratty et al., 2004).
One would expect the frequencies of the ABO blood groups to stay the same throughout
decades of life in a population, but recent United States data indicates that the percentage of
group B declines as age increases (Brecher & Hay, 2011). Although the investigators failed to
control for racial or gender differences in life expectancy, these results imply that group B is a
marker for earlier death. In contrast to these findings, a Japanese study found group B to be a
marker for longevity. This conflict is interesting, especially because the Asian population has a
larger percentage of group B than the United States population (Cavalli-Sforza et al., 1994).
These are few studies that have investigated an association between ABO blood group and
lifespan and they are limited in scope and generalizability.
As of 2014, there exists no large-scale study of ABO blood groups and lifespan in the
United States. The proposed project will further examine the relationship of ABO blood group,
transfusion and lifespan in the United States and address the limitations of this previous work by
surveying a larger sample and by controlling for race and gender. Because research has shown
an association between transfusion and adverse outcomes including mortality (Gerber, 2008;
Hebert et al., 1999; Marik & Corwin, 2008; Murphy et al., 2007; Reeves & Murphy, 2008;
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Taylor et al., 2006), history of transfusion will be included as a potential confounder. A study of
the proposed magnitude could provide a footprint for studies in other geographical regions or
countries and move towards a definitive answer regarding the relationship between ABO blood
group and lifespan.
Although many research endeavors have suggested associations between blood groups
and particular diseases or disorders (Aird et al., 1953; Albert, 1996; Hein et al., 1998; O'Donnell
& Laffan, 2001; Suadicani et al., 2007), consensus has not been reached. The relationship of
ABO blood group with disease or overall mortality is not fully understood by the scientific
community. Evidence linking ABO and length of life may imply a functional role, will allow
health care professionals to add to the overall understanding of its effect and allow further
investigation to focus at the biochemical or molecular level. Some antigens are associated with
susceptibility or protection against diseases, but these associations are statistical and the causes
are not well understood. While the biological role of blood group antigens is unknown, one is
presumed to exist based on the findings of numerous studies (Bennun, Roth, Monferran, &
Cumar, 1989; Buchanan & Highley, 1921; Cheng et al., 2005; Glass et al., 1985; Gonzalez
Ordonez et al., 1999; Kalayanarooj et al., 2007; Lin, Chang, Wu, & Cheng, 1998). Since
previous research indicates those of a particular ABO blood group might be more likely to
escape certain illnesses, then it stands to reason that ABO blood group could affect length of life.
In recent years advances in molecular genetics and cellular biochemistry have provided an
abundance of new information regarding the structure of blood group antigens. This new
information and the findings of this study will allow us to further investigate the biochemical
mechanisms responsible for a longer lifespan in a particular blood group. Additionally, results
will allow us to consider much more thoughtfully how the genetic inheritance of ABO blood
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group might relate to environmental factors to improve health or provide protection from illness.
Since all humans can be classified by ABO blood group, information regarding its effect has the
potential to impact the entire human race.
The purpose of this study is to describe the incidence of ABO blood groups in those who
expire at three tertiary care centers. Additionally, the project will examine the relationship of
ABO blood group and lifespan. The analysis will control for race, gender and history of
transfusion to determine if there is a significant difference in lifespan among persons with
differing ABO blood groups.
Aim of Study
The primary aim of this study is to determine if there is a relationship between ABO
blood groups and lifespan. Additionally, any relationship will be examined while controlling for
race, gender, location and history of RBC transfusion. The specific objectives of this study are
to: (1) synthesize patient demographic data, ABO blood group and RBC transfusion history
from three tertiary care centers, (2) calculate descriptive statistics for each ABO blood group by
race, gender, site and transfusion history, and (3) quantitatively evaluate the effect of ABO blood
group on lifespan. To meet these ends, the following preliminary questions must be answered:
What is the prevalence of each of the four ABO blood groups in the sample population? What is
the prevalence of each of the four ABO blood groups in the sample population by race? What is
the prevalence of each of the four ABO blood groups in the sample population by gender? What
is the prevalence of each of the four ABO blood groups in the sample population by site? Within
each ABO blood group, what is the prevalence of any history of transfusion?
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Delimitations and Assumptions
The target population will include all patients who die at the three tertiary care centers
during the one-year period, January 1, 2010 through December 31, 2010. Only stillborn infants
and those patients without an ABO blood group on file will be excluded from analysis. The
three tertiary care centers are Virginia Commonwealth University Medical Center in Richmond,
Virginia, Wake Forest University Baptist Medical Center in Winston-Salem, North Carolina, and
University of North Carolina Hospitals in Chapel Hill, North Carolina.
This study is based on the following assumptions: (1) the data needed can be collected
from a retrospective review of blood bank and electronic clinical records, (2) the data provided
by the clinical records is accurate, and (3) by using analysis of covariance techniques, it will be
possible to demonstrate that ABO blood group is a marker for lifespan.
Variables
The independent variable is ABO blood group and possible covariates are gender, race,
site and history of transfusion. ABO blood group refers to one of the four ABO blood groups (O,
A, B, or AB) as determined by serological tests of the antigen on the red blood cell. Gender will
be defined and recorded as male (1) or female (2). Race will be defined according to the
National Institutes of Health policy on reported race. Therefore, patients’ race will be recorded
as American Indian or Alaska Native (1), Asian (2), Black or African American (3), Native
Hawaiian or Other Pacific Islander (4) and White (5) (National Institutes of Health, 2007).

Site

refers to the tertiary care center where the sample was collected. History of transfusion refers to
transfusion of RBCs any time during the year prior to the patient’s death.
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Age will serve as the dependent variable and will represent lifespan in this study. Age
will be defined as the patient’s age at the time of death. It will be recorded as a whole number
when the patient’s year of birth is subtracted from the year of death.
Summary
The most well-known and clinically important blood group in humans is the ABO blood
group. The clinical significance of ABO blood group is evident and universally accepted with
regards to blood transfusion and pregnancy. However, the importance of ABO blood group as it
relates to other diseases or disorders and overall mortality is not fully understood by the
scientific community. Many studies have suggested associations between blood groups and
disease (Aird et al., 1953; Cheng et al., 2005; Hutson et al., 2002; Jick et al., 1969; Kalayanarooj
et al., 2007; Marinaccio et al., 1995; Shimizu et al., 2004; Suadicani et al., 2007), but consensus
has not been reached regarding overall survival or longevity. The proposed project will attempt
to answer the question, “Is there a significant relationship between ABO blood group and
lifespan?” This will be the first multi-site study in the United States to examine this relationship.
An epidemiological approach will be used to arrive at a conclusion using a retrospective study
and analysis of covariance techniques.
Organization of the Remaining Chapters
This paper is divided into five chapters. The first has been introductory. Chapter 2 is a
review of the literature and includes an overview of the reports of ABO blood group with
disease, links of ABO blood group and lifespan, links of transfusion and mortality, and the
statistical techniques used for analysis. Chapter 3 is a review of the methodology used for this
research project and chapter 4 contains the results and analysis of the research. The final chapter
includes a summary of the findings and recommendations for future research.
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Chapter Two: Literature Review

This chapter presents a review of the literature relevant to the relationship between ABO
blood groups and lifespan. It begins with inheritance and patterns of prevalence of the four ABO
blood groups and current knowledge about the evolution of the ABO blood groups. Reports on
the associations of blood groups and disease are plentiful and reviewed historically by medical
condition. Additionally, published links between ABO blood group and lifespan as well as that
of transfusion and outcomes are examined. Lifespan is described in terms of life expectancy in
the United States and the variables that may affect life expectancy.
ABO Blood Group Patterns of Prevalence
Antigens of the ABO blood group system were identified in the early 20th century, yet
their biological meaning is still largely obscure. The frequencies of blood group phenotypes are
obtained by testing the red cells of a large sample of randomly selected people of the same race
or geographic location and observing the proportion of positive and negative reactions with a
known antibody. In a given blood group system, the sum of phenotype frequencies should equal
100 percent. It has been suggested that highly polymorphic genes provide intraspecies diversity
that allows coping with diverse and rapidly evolving pathogens (Marionneau et al., 2001). Based
on the available knowledge about the genes involved in their biosynthesis and about their tissue
distribution in humans, one could postulate about the selective forces that may maintain or
propagate these oligosaccharide antigens.
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Transient polymorphism, a polymorphism in which one allele is in the process of
displacing another, is maintained only during the time that a gene is spreading through a
population (Ford, 1945). Because environments are not stable, genes or traits that hindered
survival in past, could aid in survival today. The prevalence of traits better suited for a particular
environment increase due to natural selection and adaptation. As environmental conditions
change, different phenotypes may be subject to Darwinian natural selection and have varying
survival. Therefore, we could expect that the phenomenon of transient polymorphism could be
observable when natural selection works to reduce or eliminate one phenotype or trait that is less
fit in a particular environment. In order to examine the life expectancy of ABO blood groups in
this context, it is necessary to consider the distribution of the ABO blood groups among
populations.
Evolution is a change in allele frequency over time. In addition to natural selection,
mutations and genetic drift may be sources of change in allele frequency. Mutation results when
there is a change in the DNA sequence of a particular gene. The most common mutations are
single nucleotide changes which are thought to occur in a given gene with a regular frequency.
A new mutation that is transmitted to the next generation results in a change in allele frequency,
simply because the new allele did not exist in the previous generation. In large populations,
genetic drift usually acts to counter the accumulation of mutated alleles, because high frequency
alleles have a better chance of being contributed to the next generation, while low frequency
alleles have a better chance of being lost. When dramatic examples of genetic drift occur, alleles
that were at low frequencies in the parent population can be raised to high frequencies in the new
population. An example of this is a population bottleneck in which a population is reduced to a
few individuals and the alleles of the survivors rise to higher frequencies in the populations of
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their descendants. The northern elephant seal experienced this phenomenon when humans
hunted them in the 1890s and reduced their population size to as few as 20 by the end of the 19th
century. Their population has since rebounded to over 30,000, but their genes still carry the
marks of this bottleneck and they have much less genetic variation than the original population.
The evolutionary changes that resulted in the diversity of certain ABO blood groups among
populations are unclear. It is possible to make inferences about the evolution of ABO blood
group genes by examining nucleotide sequences of the alleles (Saitou & Yamamoto, 1997).
However, it is not known for certain the exact event or events that gave rise to our current
distribution or that the distribution has ever been any different than it is today. Further, in order
to understand how natural selection pertains to ABO allele frequencies, it is necessary to
understand the biological function of the ABO antigens. Others have suggested that the
frequencies of the various alleles reflect the effect of post or ongoing epidemics and of genetic
drift (Marionneau et al., 2001) . For example, blood group antigens might interact with
pathogens that use cell surface carbohydrates as primary receptors and individuals devoid of the
antigens to which the pathogen binds may be protected from the disease. This is exemplified
with uropathogenic strains of Escherichia coli which bind glycolipids of non-secretors
(Stapleton, Nudelman, Clausen, Hakomori, & Stamm, 1992). Because they lack the FUT2 gene,
the R45 strain binds to the galactosylgloboside in the genitourinary tract of non-secretors.
However, in secretors, the FUT2 enzyme adds a fucose to the galactosylgloboside that masks this
E.coli receptor. Thus, it stands to reason that the polymorphic genes of the ABO blood group
may provide some of the diversity needed to cope with the environment, specifically, various and
rapidly evolving pathogens (Marionneau et al., 2001).
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Observations related to escape from pathogens have given rise to a theory suggesting that
the current diversity of ABO alleles is due to natural selection. Because there are so many
different pathogens that can make use of the A, B and H antigens to infect cells (Albert, 1996;
Bennun, Roth, Monferran, & Cumar, 1989; Glass et al., 1985; Kalayanarooj et al., 2007;
Lindesmith et al., 2003; Marionneau et al., 2002), natural selection favors populations comprised
of individuals with many different ABO phenotypes. If all pathogens used only the H antigen to
infect cells, then there would be selective pressure for everyone in the population to have only A
or B antigens; however, since there are pathogens that use H, A or B for infection, the population
can survive by having some individuals with no H, some with no A and some with no B
antigens. This form of selection called balancing selection, results in relatively high allele
frequencies for multiple alleles and can counter the action of genetic drift in eliminating low
frequency alleles.
United States phenotypic distribution. Three publications report on the distribution of
blood groups in the United States population. The earliest works by Buckwalter and colleagues
(1958) and Mourant and colleagues (1976), both studied populations of a single race. The
population investigated by Buckwalter and colleagues (1958) included North American Black
persons (n = 6722) while the population investigated by Mourant and colleagues, although larger
in size, included only North American White persons (n = 120,281).

The most recent study

conducted by Garratty, Glynn and McEntire (2004) resulted in the largest and most diverse
United States sample to date with a sample size of over 3 million. These investigators collected
data on allogeneic and autologous donors over a 10 year period (1991-2000) and race/ethnicity
was self-reported. Among all races/ethnicities, group O was the most prevalent and group AB
the least prevalent. The highest percentage of group O was in the Hispanic (56.5%), North
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American Indian (54.6%) and Black non-Hispanic (50.2%) populations. A summary of the
results are provide in Table 3. The prevalence of group B in the Asian population (25.4%) is
highest among the racial/ethnic groups. The ABO phenotype differences between racial/ethnic
groups all were found to be statistically significant (chi-square, p<0.0001) (Garratty, Glynn, &
McEntire, 2004).
Table 3.
ABO Blood Groups by Race/Ethnicity in the United States
Blood Group Phenotype (%)
Race/ethnicity

O

A

B

AB

White non-Hispanic

45.2

39.7

10.9

4.1

Hispanic

56.5

31.1

9.9

2.5

Black non-Hispanic

50.2

25.8

19.7

4.3

Asian

39.8

27.8

25.4

7.1

North American Indian

54.6

35.0

7.9

2.5

All

46.6

37.1

12.2

4.1

Note. Adapted from “ABO and Rh(D) phenotype frequencies of different racial/ethnic groups in the United States,”
by G. Garratty, S.A. Glynn, and R. McEntire, 2004, Transfusion, 44.

Buckwalter and colleagues’ (1958) early study of North American Black persons found
greater differences and reported higher percentage of group O and group B persons and a lesser
percentage of group A when compared to the results of Mourant and colleagues and Garratty,
Glynn and McEntire. Although Mourant and colleagues’ study was limited to only White
persons, the frequencies of ABO blood groups were similar to the overall frequencies found in
the more diverse population studied by Garratty, Glynn and McEntire.
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Regardless of ethnicity, all three studies indicate O as the most prevalent ABO blood
group, followed by A, B and then AB (Table 4). The two studies that included a Black
population show higher frequencies of group O and group B individuals and a lesser frequency
of group A individuals as compared to the White population (Buckwalter et al., 1958; Garratty et
al., 2004). Little reliable data is available on other ethnic groups in the United States. Garratty
and colleagues (2004) were able to add newer and more accurate data on the other ethnic groups
in the current United States population; however, their data represent the racial and ethnic
categories designated by United States donors. Therefore, the ABO frequencies observed may
not directly reflect the ABO frequencies of populations in the racial/ethnic group’s country of
origin, where less racial admixtures occur.
Table 4.
Comparison of ABO Blood Group Prevalence in United States by Race/Ethnicity and by Author
Phenotype (%)
Author, Date
Garratty et al., 2004

Sample
Size

Racial Makeup

2,215,623 White

B

AB
4.1

50.2 25.8 19.7

4.3

46.6 37.1 12.2

4.1

120,281 White

45.8 39.7 10.8

3.7

6,722 Black

49.1 26.5 20.1

4.3

3,086,215 All

Buckwalter et al, 1958

A

45.2 39.8 10.9

236,050 Black non-Hispanic

Mourant, et al, 1976

O

Looking at other primate species, substantial frequencies of A, B and O alleles are
reported as well. With the exception of B alleles in humans and gorillas, the frequency of ABO
alleles in other primate species differ greatly from human ABO alleles (Corvelo, Schneider, &
Harada, 2002). The ABO alleles in our species appear to be millions of years old due to the
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relatively large number of nucleotide differences among the three alleles for ABO (Saitou &
Yamamoto, 1997). Though considered to result from a mutation, it could be that the frequency
of O alleles has always been high and that it has not risen over the course of human history.
Global phenotypic distribution. The distribution of the four ABO blood types varies in
populations throughout the world. The most comprehensive data concerning blood groups in
different populations is found in Blood Groups and Diseases by Mourant, Kopéc, and
Domaniewska-Sobczak (1976). Phenotypic distribution is determined by the frequency of the
three alleles of the ABO gene in different populations. Worldwide, group O was reported to be
the most common, followed by group A, group B and group AB.
Persons of group O are the most common around the world, including the United States
and Western Europe. Among indigenous populations of Central and South America, the
frequency of group O is extremely high, approaching 100 percent. It is also high among
Australian aborigines and can range from 80-100 percent in Native American populations.
Group A is common in Central and Eastern Europe. In countries such as Austria, Denmark,
Norway and Switzerland, about 45-50 percent of the population are group A in comparison to
about 40 percent of Poles and Ukrainians. The highest frequencies of group A are found in
small, more isolated populations. For example, about 80 percent of the Blackfoot Indians of
Montana are group A. Group B is relatively common in Chinese and Indians, being present in
up to 25 percent of the population. It is less common in European countries and Americans of
European origin, being found in about 10 percent of these populations. Group B ranges up to 30
percent in some Asian populations, particularly in the Himalayas. Group AB is the rarest of
blood groups. It is most common in Japan, regions of China and in Korea, present in about 10
percent of these populations (Mourant, Kopec, & Domaniewska-Sobczak, 1976).
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Causes of global differences in ABO prevalence. With genetic drift, random effects
most likely account for the 100 percent frequency of group O in some Native South American
groups and the 50 percent frequency of group A in Australian and Native American populations.
The relative small differences in ABO frequencies between neighboring groups may be due to
gene flow between populations. The inference is that ABO prevalence is affected by natural
selection. For example, some infectious disease organisms have ABO-like antigens on their cell
walls, conferring some resistance in individuals who manufacture the appropriate antibodies, and
increasing the susceptibility of people whose blood group matches the antigens (Vogel, 1970).
Specifically, the Himalayan region has peak frequencies of group B (Mourant et al., 1976). This
area has a history of epidemics of smallpox. Vogel, Pettenkofer and Helmbold (1960) suggest
that the smallpox virus possesses material similar to the group A antigen, and this may be
responsible, in part, for resistance of smallpox infection. Pettenkofer and colleagues (1962)
asserted that in small pox infection, persons with blood groups B or O, in whom anti-A normally
occurs, have an immunological advantage over persons of blood groups A and AB, who lack this
antibody. In support of their work the authors report that of 103 Germans with severe postvaccination reactions, a significantly higher proportion belonged to groups A and AB.
Therefore, the inference is that the smallpox epidemics selected against individuals of groups A
and AB, resulting in unusually high frequencies of group B.
It is also possible that there are antenatal processes having a selective effect on the ABO
blood group frequencies. ABO incompatibility between the mother and fetus would select for
fetuses with matching or compatible blood groups, thus favoring group O. Indeed the high
frequency of group O in isolated populations in and around Europe, on islands, mountain ranges,
and deserts, to which travel has been slower and more difficult may be result of ABO differences
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between mother and fetus (Mourant et al., 1976; Mourant, Kopec, & Domaniewska-Sobczak,
1978). This clearly has not happened in most populations, and evidence of other processes must
be sought and alternate explanations must be considered. The high frequency of group O may
represent the blood group composition of one or more early populations of the region who were
driven by later immigrants into these relatively inaccessible areas. If some common epidemics
do favor persons of group A or groups A and B, then it may be that in areas of easier
communications and transmissions of infections, the processes favoring group O are partly
balanced by these others, leading to higher equilibrium frequencies of A and B in the more
continental areas.
Associations of ABO Blood Groups and Disease
From 1917 to 1940 there were already more than 300 reports in the literature showing a
statistical relationship of certain ABO blood groups with certain medical conditions or
characteristics such as criminality or personality traits. Geneticist, E.B. Ford (1945), said,
“It is reasonable to conclude, from what we know of polymorphism, that individuals belonging
to the different blood groups are not equally viable…A valuable line of enquiry which does not
yet seem to have been pursued in any detail would be to study the blood group distributions in
patients suffering from a wide variety of diseases. It is possible that in some conditions,
infectious or otherwise, they would depart from their normal frequencies, indicating that persons
of a particular blood group are unduly susceptible to the disease in question.” (p. 85).
Clinical Significance of ABO Blood Groups
A variety of medical literature has been concerned with epidemiological studies related to
ABO blood groups and associated mortality, diseases and disorders. However, only a small
number of issues have been accepted by the scientific community as clinically significant. These
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include the hemagglutination problems of incompatible ABO blood type in transfusion and
pregnancy. In fact, the chemical structures were labeled as RBC antigens due to the problems
they caused in transfusing blood (Garratty, 2000). Most transfusions provide safe and effective
temporary replacement of blood components. However, severe hemolytic reactions can occur
when transfused RBCs interact with preformed antibodies in the recipient. The interaction of
antibody with antigen can initiate a sequence of neuroendocrine responses, complement
activation, coagulation effects, and cytokine effects that result in clinical manifestations of an
acute hemolytic transfusion reaction (Roback, Grossman, Harris, & Hillyer, 2011). Most severe
acute hemolytic transfusion reactions results from transfusion of ABO-incompatible RBCs
(Sazama, 1990).
Levine (1943) demonstrated that hemolytic disease of the fetus and newborn (HDFN)
was caused by immunization of the mother by paternally derived fetal antigens she lacked.
Maternal IgG antibodies cross the placenta, sensitize fetal RBC antigens and can cause
bilirubinemia, anemia and heart failure. Because IgG is the dominant class of Anti-A,B in group
O persons, infants of group O mothers are at a higher risk of ABO hemolytic disease of the
newborn. Although small quantities of IgG antibodies are present, IgM is the predominant
immunoglobulin class of anti-A and anti-B in group B and group A persons, respectively
(Rawson & Abelson, 1960a; Rawson & Abelson, 1960b). Because IgM does not cross the
placenta, infants of group A and group B mothers are at a lesser risk of ABO hemolytic disease
of the newborn (Kochwa, Rosenfield, Tallal, & Wasserman, 1961).
ABO blood group and disease. Differences in ABO blood groups are determined by
antigens in the outer carbohydrate coating (glycocalyx) of erythrocytes (Lowe, 1994). Because
these antigens are present in most tissues as well (Oriol et al., 1981; Szulman, 1960; Triadou,
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Audran, Rousset, Zweibaum, & Oriol, 1983; Trickett, Evans, MacIver, Smith, & Slapak, 1983),
differences in the glycocalyx expressed by cells might elicit differing responses in biomedical
phenomena in other diseases or disorders apart from the hemagglutination events already
discussed. Although many studies have examined the relationship of ABO blood group with
disease, there remains a lack of consensus regarding statistical and clinical associations. Studies
on this association date back as far as 1927, and the most noteworthy are reviewed here.
Prokop and Uhlenbruck (1969) published a review of early literature of associations of
blood groups and disease. Although most of the research examines associations of ABO with
disease, early papers describe associations with hangovers, teeth or personality characteristics.
One report indicated that hangover was worse in individuals of group A and that group B
individuals defecate the most (Warnowsky, 1927). Additionally, in 1930 an investigator
reported that group O persons have the best teeth (Suk, 1930). Further there are several papers
and books published relating ABO blood groups to personality characteristics. For example, in
his book, Character, Blood Groups and Constitution, Schafer (1941) found that military
personnel who were group O had less satisfactory strength of character and personality, and that
group B individuals were more impulsive. Bohmer (1927) and others have suggested an
association with group A and criminality (as cited in Garratty, 1996; Palmieri, 1929). These
early reports lacked adequate sample sizes and the rigor of modern statistical methods, but
demonstrate the numerous speculations that have been made regarding associations with ABO.
Reports of such associations with characteristics persist today. The book entitled “You are Your
Blood Type – The Biochemical Key to Unlocking the Secrets of Your Personality” was
published in 1988 (Nomi & Besher, 1988). This book details how Japan’s largest companies
use blood types in marketing and for evaluating job applicants. In 1998, one of the New York
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Times best sellers was a book titled, “Eat Right 4 Your Type” (D'Adamo, 1997). The same
author wrote a subsequent book that describes special diets for each ABO blood group
(D'Adamo, 1999). The author hypothesizes that the original blood group was O and that these
people were hunter-gatherers and meat eaters. In contrast, later generations who were group A
became farmers and ate more grain and vegetables, and drank milk; groups B and AB were said
to be the last to emerge because of racial intermingling (D'Adamo, 1997). However,
contemporary molecular studies show that the O gene appears to be a mutation of the A gene,
and thus group O appeared later than the other ABO groups (Saitou & Yamamoto, 1997).
Although there are thousands of publications on the associations of blood groups with
disease, many are based merely on statistical associations without a basis for biological or
physiological association (such as associations with hangovers and personality characteristics).
Additionally, most of the early studies are controversial because they were small studies, had
inadequate controls or had been analyzed incorrectly. However, there exists a general pattern
that has emerged from the large body of statistical data on malignancy, coagulation and infection
(Table 5) (Garratty, 2000). Many of these early statistical associations now have some
associated scientific findings (such as membrane chemistry, tumor immunology and microbial
receptors for infectious disease) that support a scientific rationale for the statistical associations
(Garratty, 1994).
The scientific literature provides a variety of data regarding the relationship of ABO
phenotype with diseases and disorders, as well as survival (Albert, 1996; Hein, Suadicani, &
Gyntelberg, 1998; O'Donnell & Laffan, 2001; Suadicani, Hein, & Gyntelberg, 2007). Reports of
positive correlations exist for a particular ABO blood group with infectious disease, deep vein
thrombosis (DVT), heart disease, pulmonary function, malignancy, obesity, survival, and even
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Table 5.
Statistical Relationship of ABO Blood Groups with Disease
Disease

A>O

Malignancy

X

Thrombosis

X

O>A

Peptic Ulcers

X

Bleeding

X

B/AB > A/O

E. coli/Salmonella infections

X

Note. Adapted from “Blood Groups and Disease: A Historical Perspective,” by G. Garratty, 2000, Transfusion
Medicine Reviews, 14.

behavioral traits (Table 6). The following summary is organized by disease and emphasizes any
association found between ABO blood group and disease or mortality.
Infectious disease. Studies of the relationship of ABO blood group and infectious
disease are plentiful in the literature and include Helicobacter pylori, Vibrio cholerae,
Escherichia coli, Norwalk virus, Severe Acute Respiratory Syndrome and Dengue Fever (Aird,
Bentall, Mehigan, & Roberts, 1954; Alkout, Blackwell, & Weir, 2000; Boren, Falk, Roth,
Larson, & Normark, 1993; Cheng et al., 2005; Clark et al., 1956; Guillon et al., 2008; Hein et al.,
1998; Hutson, Atmar, Graham, & Estes, 2002; Kalayanarooj et al., 2007; M. M. Levine et al.,
1979; Marionneau, Airaud, Bovin, Le Pendu, & Ruvoen-Clouet, 2005; Mentis et al., 1991;
Sharara, Abdul-Baki, ElHajj, Kreidieh, & Kfoury Baz, 2006). The A, B, H and other related
carbohydrate antigens are highly expressed on gut cells in the gastric and duodenal regions
(Glynn, Holborow, & Johnson, 1957; Green et al., 1988) and have been associated with
susceptibility to pathogens, and in particular, gut pathogens. Evidence has accumulated for
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Table 6.
ABO Blood Group Associations by Disease/Disorder

Disease/Disorder
Helicobacter pylori

Vibrio cholerae

Escherichia coli
Norwalk Virus

Severe Acute Respiratory
Syndrome (SARS)
Dengue Fever & Dengue
Hemorrhagic Fever (DHF)
Deep Vein Thrombosis
(DVT)
Heart Disease

Pulmonary Function

Author, Year of Publication
Aird et al., 1954
Clark et al., 1956
Rotter, 1983
Mentis et al., 1991
Davidson & Triadafilopoulos, 1992
Boren et al., 1993
Lin et al., 1998
Hein et al., 1998
Levine et al., 1979
Glass et al., 1985
Albert, 1996
Armstrong et al., 1999
Shimazu et al., 2000
Hutson et al., 2002
Lindesmith et al., 2003
Marionneau et al, 2005
Cheng et al., 2005
Guillon et al., 2008
Kalayanarooj et al., 2007
Jick et al., 1978
Koster et al., 1995
Robert et al., 2000
Medalie et al., 1971
Garrison et al., 1976
Rosenberg et al., 1983
Whincup et al., 1990
Meade et al., 1994
Green et al., 1995
Suadicani et al., 2000
O’Donnell & Laffan, 2001
Ketch et al., 2008
Anvari et al., 2009
Menkes et al., 1984
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Association with
ABO Group
O
O
O
O
O
O
O
O
O
O
O
B (protective effect)
B (protective effect)
B (protective effect)
B (protective effect)
A
O (protective effect)
O (protective effect)
AB (more severe case
of the disease)
A, B, AB
A, B, AB
A, B, AB
A, B, AB
Non-O
A
A
AB
A, B, AB
O
O
Non-O
O
A

Table 6. Continued
Association with
ABO Group
A
A
A
O
O

Disease/Disorder
Malignancy

Author, Year of Publication

Obesity

Suadicani et al., 2007

Intelligence Quotient (IQ)

Gibson et al., 1973

Suicide

Lester, 1987 & 2004

O (protective effect)

Temperament

Neumann et al., 1991
Shapiro et al., 1977

O (type A behavior)
O

Zonda & Lester, 2002
Shimizu et al., 2004
Hong et al., 2006
Brecher & Hay, 2011
Vasto et al., 2011

O

Bipolar Disorder
Survival/Mortality

Aird et al., 1953
Lee et al., 1990
Marinaccio et al., 1995
Suadicani et al., 2007

A2 and O

B (protective effect)
B (protective effect)
B
No Association

associations between ABO blood group and gastric ulcer and carcinoma (Boren et al., 1993;
Langman & Doll, 1965; Merikas, Christakopoulos, & Petropoulos, 1966).
In 1954, Aird reported that group O individuals were more likely than group A, B or AB
individuals to have peptic (gastric and duodenal) ulcers. Taking the ABO group and secretor
status into account yielded a relative increase of 35 percent in group O secretors among those
with peptic ulcer when compared to a control group. Langman and Doll (1965) and Merikas and
colleagues (1966) also investigated this association and supported the association of group O
with ulcers and bleeding ulcers. Using blood donors as the control group, the original study was
performed on only hospital patients, thus creating a potential bias if only patients with bleeding
ulcers were admitted. Within this context, it has also been shown that among the cases of
duodenal ulcers, the group O patients are more likely to bleed (Langman & Doll, 1965). Thus,
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the bleeding tendency that brought the patient to the hospital may have accounted for the excess
of group O reported by Aird and colleagues (1954). In 1993, Boren and colleagues reported that
Lewis blood group antigen, Leb (which has close associations with the ABO system), is the
receptor for Helicobacter pylori. H. pylori is associated with gastric adenocarcinoma and is
thought to be a major cause of gastric ulcers (Boren et al., 1993).
Additionally, there is evidence that suggests that the mosquito, Anopheles gambiae,
recognizes ABO blood group variation and is selective in its feeding, with a preference for blood
group O (Wood, Harrison, Dore, & Weiner, 1972). The basis for this recognition and selection
is not obvious, although ABH blood group substances do occur on skin cells and have been
reported in sweat of secretors (Roback, Grossman, Harris, & Hillyer, 2011; Saito, 1994). This
finding could be of great importance in infectivity rates, the development of acquired immunity
and natural selection for ABO blood groups in malarious regions.
Individuals possess antibodies directed toward the A or B antigen absent from their own
RBCs. One hypothesis for the development of these antibodies is based on the fact that the
configurations that confer A and B specificities also exist in other biological entities, notably
bacterial cell walls. Springer and colleagues (1961) showed that many gram negative organisms,
such as Escherichia coli, have chemical moieties on their membranes resembling A and B blood
group antigens. A separate, later report indicates that this is the stimulus for anti-A and anti-B
production by human infants (Springer & Horton, 1969). Bacteria are widespread in the
environment and their presence in intestinal flora, dust, food and other widely distributed agents
ensures a constant exposure of all persons to A-like and B-like antigens (Roback, Grossman,
Harris, & Hillyer, 2011). Immunocompetent persons react to the environmental antigens by
producing antibodies to those that are absent from their own systems. This environmental
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explanation for the emergence of anti-A and anti-B remains a hypothesis that has not been
proven, but there is evidence that anti-B recognizes and kills E. coli in vitro (Check, O'Neill,
O'Neill, & Fuscaldo, 1972; Muschel & Osawa, 1959). These studies illustrate an increase in the
bactericidal reaction when E. coli is mixed with anti-B and lend support to the hypothesis of
ABO antibody development. However, it is not known whether ABO antibodies can destroy
bacteria in vivo and, therefore, serve a functional role or offer a protective effect. Although this
remains uncertain, others have suggested that the differences seen in the prevalence of ABO
blood groups in different parts of the world may be attributable to epidemics that have occurred
in the past (Mourant et al., 1976; Mourant et al., 1978).
Deep vein thrombosis. Deep vein thrombosis (DVT) refers to a clot that forms mainly in
the larger veins of the leg. This clot can interfere with blood flow, and it may break off and
travel through the bloodstream, or embolize. The embolus can lodge in the brain, lungs, heart or
other area, severely damaging that organ (Vascular Disease Foundation, 2007).
Thrombophlebitis occurs when a blood clot causes inflammation in one or more veins. The
affected vein may be near the surface of the skin, or deep within a muscle (Vascular Disease
Foundation, 2007). ABO blood group distribution has been associated with thrombotic disease
with an excess of the non-O (in other words, A, B, and AB) blood group in patients with venous
thrombosis (Jick et al., 1969). In 1978, Jick and colleagues examined the association between
thrombophlebitis and ABO phenotype in 86 cases with a discharge diagnosis of thrombophlebitis
of the lower extremity and 344 matched control patients. The authors found that the association
between non-O blood type and thrombophlebitis of the lower extremity was strongest among the
younger patients and women (Jick, Dinan, Herman, & Rothman, 1978). A later case-control
study added support to Jick and colleagues’ findings and demonstrated that non-O blood group
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increased the risk of deep vein thrombosis (Koster, Blann, Briet, Vandenbroucke, & Rosendaal,
1995). Similar findings were noted in a 2000 study of subjects with an identified thrombosis risk
factor such as the factor V Leiden mutation (Robert et al., 2000).
Heart disease and coagulation. The literature shows a tendency for group O individuals
to bleed and non-O groups to thrombose (Jick et al., 1978; Koster et al., 1995; Robert et al.,
2000). One report describes group A individuals as having a higher average level of factor VIII
in their plasma than group O individuals (Preston & Barr, 1964). Preston and colleagues (1964)
suggested that the different levels of factor VIII in the plasma, even within the normal range,
may determine whether clinically detectable bleeding may occur from an ulcer or a blocked or
narrowed blood vessel. Another investigator found a higher frequency of group O in the
atherosclerotic patients with increased mural atheroma when compared to the frequency of group
O in the occlusion group (Kingsbury, 1971). This investigator attributed these findings to a
tendency of the group O patients to hemorrhage (rather than thrombose) into the arterial walls,
thus sustaining more tissue damage.
Several other works have confirmed the association of group A with a higher factor VIII
level (Garratty, 1994; Souto et al., 2000); and there also have been associations with other
coagulation factors, such as von Willebrand Factor (VWF) (Garratty, 1994; Gonzalez Ordonez,
Medina Rodriguez, Martin, Alvarez, & Coto, 1999). VWF plays an essential role in hemostasis
by participating in platelet adhesion and aggregation and stabilizing Factor VIII. Deficiency or
abnormalities of VWF leads to von Willebrand disease (VWD) (U.S. National Library of
Medicine & National Institutes of Health, 2007a). Additionally, the level of VWF appears to
correlate with ABO blood group (Gill, Endres-Brooks, Bauer, Marks, & Montgomery, 1987;
McCallum, Peake, Newcombe, & Bloom, 1983; Mohanty et al., 1984; Orstavik et al., 1985;
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Stormorken & Erikssen, 1977). Group O individuals have been reported to have lower plasma
concentrations of VWF, than persons with other blood types (Green, Jarrett, Ruth, Folsom, &
Liu, 1995; O'Donnell & Laffan, 2001). However, these studies have demonstrated a relationship
between ABO blood group and levels of factor VIII and VWF only by association and not by
linkage studies. Also unclear from these reports is whether the ABO locus exerts a functional
effect directly on these plasma factors or whether the ABO locus is in linkage disequilibrium
with another locus that controls these factors.
Souto and colleagues (2000) applied statistical methods combining linkage and
association tests in a pedigree-based sample using ABO genotypes. This allowed for
differentiating AO from AA and BO from BB. The results demonstrated significant linkage
between the ABO locus and VWF antigen (p=0.00075). In addition, factor VIII coagulant
activity and activated partial thromboplastin time showed suggestive linkage with the ABO locus
(p=0.10 and p=0.13). All three phenotypes (A, B and AB) showed significant differences
between OO and non-OO genotypes. In addition, VWF antigen exhibited significant differences
between O heterozygotes and non-OO homozygotes. This study is unique because it used a
combined linkage and association test, which indicated that the ABO locus itself has a functional
effect on these phenotypes. Since elevated VWF carries increased risk for ischemic heart
disease, these studies support the suggestion that cardiovascular events might be less frequent in
group O individuals.
Because an association with the Le(a-b-) phenotype and increased risk of coronary heart
disease for older males had been reported (Hein, Sorensen, Suadicani, & Gyntelberg, 1992),
Green and colleagues (1995) investigated the relationship between Lewis phenotype and
cardiovascular risk factors in 1714 participants in their Coronary Artery Risk Development in
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Young Adults Study. Although no significant differences were observed among Lewis
phenotypes, in White men with blood groups A, B or AB and the Le(a-b-) phenotype,
significantly higher levels of factor VIII and VWF factor were observed than those with other
Lewis phenotypes. The results indicated a significant interaction between ABO blood group and
Lewis phenotype in terms of relationship to factor VIII. A similar trend was observed in Black
men with blood type A, B or AB and the Le(a-b-) phenotype for factor VII/VWF and in women
with blood type A, B or AB and the Le(a-b-) phenotype for factor VIII. The authors concluded
that the data suggest the Le(a-b-) phenotype and blood groups A, B and AB (by virtue of their
association with raised levels of factor VIII and VWF), may be risk markers for future
cardiovascular disease (Green et al., 1995).
An increased risk of heart disease has been found for non-O individuals (Garrison et al.,
1976). The Framingham Heart Study cohort was followed for the occurrence of cardiovascular
events for a period of 10 years. A significant association was found between ABO blood group
and intermittent pain caused by too little blood flow (claudication), with blood group O showing
the lowest rates. Slight (although non-significant) excesses for certain other heart disease events
were also found in non-O individuals. Serum cholesterol showed marginally significant but
consistent elevations in non-O subjects, but the increased risk in non-O individuals was found to
occur independently of the known intermittent claudication risk factors. Because the observed
relationship between blood group and intermittent claudication occurred independently of the
usual atherosclerotic risk factors, the authors concluded that ABO blood group, should be
considered in the pathogenesis of intermittent claudication, possible through an effect on clotting
(Garrison et al., 1976).
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Jick and colleagues (1978) used a case-control design to study the role of estrogens and
other factors in myocardial infarction (MI) in young women. The study included 83 women less
than 46 years old with acute MI and 154 controls. In this early study, non-O blood group was
determined to be positively associated with MI. A subsequent case-control study aimed to
evaluate the risk factors for first nonfatal MI in women younger than 50 years old, and included
255 women with MI and 802 controls (Rosenberg et al., 1983). Results indicated that blood
group A was a factor significantly associated with MI in women of this age group.
Suadicani and colleagues (2000) tested the hypothesis that an uneven socioeconomic
distribution of ABO phenotypes could contribute to an explanation for the association of
socioeconomic status with the risk of ischemic heart disease. This prospective study controlled
for age and other relevant confounders, such as smoking, physical activity, wine consumption,
and serum lipids. The study participants were enrolled in the Copenhagen Male Study (CMS)
and were 2993 men aged 53-74 without overt ischemic heart disease. The outcome measure was
the incidence of ischemic heart disease in an 8-year follow-up. The results indicated that ABO
phenotype was not a confounder for the association of socioeconomic status with the risk of
ischemic heart disease. However, ABO blood group was a strong risk or effect modifier for the
association of socioeconomic status with the risk of ischemic heart disease in group O men. The
authors concluded that their findings helped to clarify the roles of socioeconomic status and
ABO blood group as cardiovascular disease risk factors (Suadicani, Hein, & Gyntelberg, 2000).
Most recently Anvari and colleagues (2009) examined over 10,000 Iranian patients
awaiting coronary artery bypass graft surgery in an effort to determine if ABO blood group is
related to ischemic heart disease. Using Chi Square analysis, this prospective study reported a
statistical difference between gender and ABO (p = 0.074 for group O and p = 0.031 for group

38

A), with the number of group A male patients differing from the number of group A female
patients. However, males were overrepresented in the sample population (71.9%). More
importantly, the authors also reported that group B was less susceptible to hyperlipidemia
compared to other groups (p = 0.024) and suggested that group B is a protective factor for
cardiovascular disease risk. An additional conclusion was the prevalence of coronary artery
disease in group O as markedly higher than in all other ABO blood groups. The authors found
diabetes, hypertension, and cerebrovascular disease significantly more common in the group O
patients compared to all other ABO blood groups (Anvari et al., 2009). Although the sample
appears to be from a single ethnic group, it is not clear if the authors controlled for gender or age.
The results of Anvari and colleagues (2009) differ from other United States (Ellison et
al., 1999; Ketch et al., 2008; Rosenberg et al., 1983) and European (Meade et al., 1994; Medalie
et al., 1971; Whincup, Cook, Phillips, & Shaper, 1990) studies which found more cardiovascular
events in non-group O patients. The results of Ketch and colleagues (2008) point to higher
thrombosis in the non-group O patients despite less extensive atherosclerosis. However, when
they examined outcomes at one year, the groups were similar. Additionally, the research by
Ketch and colleagues is limited due to its retrospective nature and smaller sample size (1198).
Neither of these studies measured VWF or Factor VIII levels which may have prognostic value
independent of ABO group (Jager et al., 1999) or accounted for environmental factors (such as
diet) that could be a stimulus for cardiovascular disease.
Pulmonary function. Menkes and colleagues (1984) performed an epidemiologic study
of obstructive airway disease using cross-sectional and longitudinal data to investigate
relationships among risk factors, pulmonary function and mortality. In the 2539 non-patient
adults, 11 potential risk factors, including ABO group, were found to be significantly associated
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with airway obstruction. When combinations of risk factors were examined, cross-sectional data
indicated that some of these factors were important risk factors in cigarette smokers but less
evident in never smokers. ABO blood group, familial component, coffee drinking and diet soda
intake were related to marked differences in lung function in cigarette smokers, but had little
impact on never smokers. Consistently greater declines of lung function were noted in males,
older subjects, smokers, Whites, and individuals carrying the type A blood group allele (Menkes,
Cohen, Beaty, Newill, & Khoury, 1984).
Malignancy. Studies of the association between ABO blood group and malignancy have
included stomach cancer, gynecological tumors, and lung cancer. Many early studies lacked
large sample sizes and adequate controls. The first reliable report was published by Aird and
colleagues (1953), who showed that 20 percent more group A individuals had cancer of the
stomach than did group O individuals. This was a large study, and its results have been
confirmed in subsequent reports (Vogel & Krugr, 1968; Vogel, 1970).
Lee and colleagues (1990) carried out descriptive and analytical studies to examine the
epidemiological characteristics and multiple risk factors of stomach cancer in Taiwan. The
authors found that group A was associated with the development of stomach cancer with an odds
ratio of 1.61, p<0.01 (Lee et al., 1990). Marinaccio and colleagues (1995) conducted a study to
examine gynecological tumors and ABO phenotype. This report was a retrospective analysis of
968 women affected by gynecological tumors conducted to assess the existence of a difference in
survival between patients with different blood groups. The authors reported a better 5-year and
10-year survival associated with group O when compared with group A. Specifically,
endometrial and ovarian cancer occurred more frequently in group A women than those in the
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other blood groups and in the same tumors, group A was associated with a poorer prognosis
(Marinaccio et al., 1995).
The Copenhagen Male Study supported the concept that compared with other ABO
phenotypes, males of phenotype O may exhibit a stronger systemic inflammatory response
following occupational exposure to particulate air pollution (Suadicani, Hein, & Gyntelberg,
2002). The increasing recognition of inflammation as a contributing factor to the development
of cancer motivated Suadicani and colleagues to hypothesize that the role of inflammationrelated risk factors for lung cancer may depend upon ABO blood group. Consequently,
Suadicani and colleagues (2007) examined the relationship of lung cancer mortality, risk of
lifestyle and occupational factors previously linked to inflammation and ABO phenotype. The
authors concluded that the predictive role of inflammation-related risk factors for lung cancer
mortality was significantly stronger among males of phenotype O than A (Suadicani et al.,
2007).
A review of the literature indicates that associations of ABO groups with malignancy,
overall group A predominates over group O (Aird, Bentall, & Roberts, 1953; Lee et al., 1990;
Marinaccio et al., 1995) . Altered expression of the ABH antigens have been found on all types
of carcinomas and are often associated with unfavorable prognosis (S. Hakomori, 1996; Le
Pendu et al., 2001). As cells (in tissue) become malignant, they tend to lose normal antigens and
acquire new antigens. These “new” antigens may be precursors of antigens normally present or
antigens that should not be present on a genetic basis (Garratty, 2000). Oh-Huti (1949) was the
first to describe a loss of ABH antigens from malignant cells, and his report was confirmed by
Masamune and colleagues (1953), Kay and Wallace (1961), Nairn and colleagues (1962) and
Davidsohn (1972). It has been proven that ABO antigens diminish on malignant cells as the
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malignancy progresses and the loss of A, B, and H antigens is proportional to the metastatic
potential of the tumor (Garratty, 1994).
Obesity. The definition of obesity varies; but in general, it is a chronic condition defined
by an excess amount body fat. Obesity is not just a cosmetic consideration, but also increases
the risk of insulin resistance, type 2 diabetes, heart attack and stroke (U.S. National Library of
Medicine & National Institutes of Health, 2007b). Suadicani and colleagues (2002) identified a
relationship between occupational airborne pollutants, ABO phenotypes, and risk of ischemic
heart disease when they found that long-term exposure to air pollutants was associated with a
significantly increased risk of heart disease among men with phenotype O, and not among men
with other ABO phenotypes. Long-term occupational exposure (> 5 years of exposure) to
various airborne pollutants such as soldering fumes, welding fumes and plastic fumes was
associated with a significantly increased lifetime prevalence of myocardial infarction. Odds
ratios (95% confidence limits) for these factors were 3.0 (1.6–5.8), p = 0.002, 2.1 (1.05–4.2), p =
0.05, and 8.3 (2.6–27.0), p = 0.003. In this report, the authors suggested that the biological
pathway could be a stronger systemic inflammatory response in men with blood group O.
Several inflammatory mediators likely to increase the risk of ischemic heart disease have been
linked also to obesity, suggesting that long-term exposure to airborne pollutants might play a role
in the etiology of obesity. As a result, in 2005, Suadicani and colleagues tested the hypothesis
that long-term occupational exposure to airborne pollutants would be more strongly associated
with obesity in men with phenotype O than in men with other ABO phenotypes. The subjects
were participants of the Copenhagen Male Study. The authors found no differences in the
prevalence of obesity between men with the O phenotype and men with other phenotypes.
However, only among men with the O phenotype was long-term occupational exposure to
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various respirable airborne pollutants associated with an increased prevalence of obesity. Even
after adjustment for lifestyle factors, age and social class, the authors found a relationship of
airborne exposures with obesity in men with phenotype O (Suadicani, Hein, & Gyntelberg,
2005).
The authors suggest these observations are biologically plausible since air pollution is a
heterogeneous, complex mixture of gases, liquids, and particulate matter. Systemic
inflammatory responses have been described by Yudkin and colleagues (2000), who suggested
that interleukin-6 (IL-6) may be the link connecting coronary heart disease and obesity
(Suadicani et al., 2005). Additionally, there is evidence that individuals of blood type O have an
increased inflammatory response when exposed to H. pylori, with a significantly increased
release of IL-6, one of the inflammatory parameters also previously linked with risk of ischemic
heart disease (Alkout et al., 2000) and obesity (Das, 2001; Yudkin, Kumari, Humphries, &
Mohamed-Ali, 2000). Researchers offer that this finding of a strong relationship between longterm exposure to airborne pollutants, ABO phenotypes, and risk of obesity could lead to new
possibilities for clarifying mechanisms underlying the global obesity epidemic (Suadicani et al.,
2005).
Behavioral traits. In addition to diseases, the relationship between behavioral traits or
personality characteristics such as intelligence quotient (IQ), suicide, temperament, and bipolar
disorder with ABO blood groups has been examined in various studies. In a 1973 letter to
Nature, Gibson and colleagues described an association they found between IQ and ABO
phenotypes. Their data showed a significant difference in mean age-adjusted IQ between some
of the ABO phenotypes. In particular, the A2 group had the highest mean IQ and the A2 and O
phenotypes each had significantly higher mean IQs than the A1 phenotypes (Gibson, Harrison,
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Clarke, & Hiorns, 1973). Although some publications have no scientific basis (e.g., a book
entitled, “You are Your Blood Type – The Biochemical Key to Unlocking the Secrets of Your
Personality” (Nomi & Besher, 1988)), other associations have stronger biological foundations
and some can be linked to overall health and mortality.
In 1977, Shapiro and colleagues studied 66 manic-depressive patients and identified them
as either bipolar or unipolar. Within this group, they found that a significantly higher percentage
of bipolar patients (than unipolar patients) were group O (Shapiro, Rafaelsen, Ryder, Svejgaard,
& Sorensen, 1977). A 2002 study of type I bipolar patients in Budapest confirmed these results
(Zonda & Lester, 2002).
Lester (1987) has explored the association between the distribution of blood types in
nations and their suicide and homicide rates. He found that in 17 industrialized nations, the
percentage of people with group O blood was negatively associated with their suicide rates but
was not associated with their homicide rates (Lester, 1987). In 2004, Lester looked at a larger
sample of nations. He found that the greater the proportion of people with group O blood in a
nation, the lower the suicide rate and the higher the homicide rate (Lester, 2004). The
proportions with group A and AB blood were associated with higher suicide and lower homicide
rates (Lester, 2004). Even when the author controlled for gross domestic product per capita, it
did not change these patterns.
There have been some correlations found between physical dysfunctional states and
blood groups. Since some of these disorders have possible psychosomatic components, such as
duodenal ulcer or MI, Neumann and colleagues (1991) wanted to focus on the relationship
between blood groups and various indices of behavior patterns in young patients who had an
initial MI. Examples of the behavior patterns used were type A behavior scores and anger
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ratings. Results indicated that patients with the group O phenotype scored higher than patients
with the group A phenotype on type A behavior scales. Group B patients responded on several
scales between those with group A and group O (Neumann, Chi, Arbogast, Kostrzewa, &
Harvill, 1991). Authors suggested that these results might be used in future research to predict
MI.
Summary of ABO blood group associations with disease. The statistical associations
of ABO blood group with disease that are of most interest are those with malignancy, peptic
ulcers, coagulation and infection (Table 5). Many of the early statistical associations now have
some associated scientific findings that suggest a rationale for the associations (Garratty, 1994).
Table 6 provides a more detailed historical perspective of the published works in each of the
broad disease or disorder categories covered in this manuscript. The diseases or disorders in the
table had a positive association with the ABO indicated in the table, unless otherwise noted that
the ABO was found to have a “protective effect” for the particular disease or disorder.
ABO blood groups and survival. While the biological role of ABO antigens is
uncertain, it has been postulated that the polymorphic genes of the ABO blood group provide the
diversity needed to survive changing environmental conditions and evolving pathogens
(Marionneau et al., 2001). Although there have been many research endeavors regarding the
associations of ABO blood groups with specific diseases, fewer have examined an association
with ABO blood groups and overall survival or lifespan. What follows is a review of the few
studies that have examined ABO blood group and lifespan from a macro-perspective.
A 2006 study addressed the effectiveness of liver transplant, as measured by 1-year
survival (Hong et al., 2006). The authors performed a retrospective review of 1164 liver
transplant recipients in Canada, and ABO blood group was included as an independent variable.
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The results indicated that the patient’s ABO blood group had a significant effect on recipient
survival. Specifically, group B patients had a 12 percent higher survival probability; and group
AB patients had a 7 percent lower survival probability compared to group O (Hong et al., 2006).
The authors offer no possible explanations for these findings and merely state that this
phenomenon is not clearly understood.
Another study investigated the association between blood groups and life expectancy
(Shimizu et al., 2004). The authors compared frequencies of ABO blood groups in 269
centenarians (persons over 100 years old) living in Tokyo and those in 7153 regionally matched
controls. Differences between centenarians and controls and between observed and expected
frequencies were investigated by Chi Square tests. Group B was observed more frequently in
centenarians than in controls (2 = 8.41, p = 0.04). This suggests that group B might be
associated with exceptional longevity. This conclusion is limited since the predominance of
blood group B among centenarians was not statistically significant. Additionally, the authors
tabulated diagnoses of hypertension (n=78), cardiovascular disease (n=51), apoplexy (n=37),
diabetes (n=9), femoral fracture (n=66), malignancy (n=24), and chronic lung disorder (n=29) in
the centenarians. One-third of the centenarians were free of these diseases, but this did not
correlate with the group B centenarians. Seventy-seven percent of the group B centenarians had
one or more of these diagnoses. The authors concluded that this finding indicates that group B
persons are more likely to survive serious disease rather than escape it. The authors did not
report disease frequency for the control group. Because plasma concentrations of VWF (a
cardiac risk factor) are lower in group O (O'Donnell & Laffan, 2001), one would expect a
predominance of group O; but the frequency of group O in centenarians was lower (Shimizu et
al., 2004). Shimizu and colleagues (2004) do not offer a biological explanation for these
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findings except to state that group B contributes to longevity by some biochemical mechanism
that allows this group to better survive disease.
To assess the validity of Shimizu and colleagues’ (2004) observations, Brecher and Hay
(2011) collected data on the ABO blood groups of patients who died in a United States tertiary
care hospital over a 1-year period. If group B was a marker for a longer lifespan, it would be
expected that the percentage of group B patients would rise with age at the time of death and
those of other blood groups would decline. A total of 772 patients were included in the study
and were presented as ABO proportion stratified by age (Brecher & Hay, 2011). The researchers
found that the percentage of group B patients declined with age, and this result was statistically
significant (p<0.01; R2 = 0.68). None of the other blood groups showed a statistically significant
increase or decrease when plotted against decade of death (Brecher & Hay, 2011). Additionally,
when survival curves for the ABO blood groups were compared, group B exhibited decreased
survival compared to the other groups (Figure 1). Inspection of the survival curves shows that
most of the difference occurs at the younger ages. Although the aim of this study was to
investigate a relationship of ABO blood group with longevity, when examining the frequencies
of death stratified by decade, it is important to note that the sample revealed a disproportionate
number of deaths in the first decade of life. It is not possible from the data here to theorize a
cause for this, but it is important to note since diseases processes in the young may be different
than older patients. Overall, these results suggest that group B is not a marker for longevity, but
may actually be a marker for earlier death. Although these results are pertinent to the United
States population, and provide interesting information, the authors did not control for race or
gender, and did not collect information on disease comorbidities.
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Figure 1. ABO Blood Group Survival Comparison.
Survival curves showing the decreased survival of people with group B blood compared with
people with groups O, A, and AB over time (P < .01). There was no statistical difference in
groups A, O, and AB (P = 0.47). From “ABO Blood Type and Longevity” by M.E. Brecher and
S.N. Hay, 2011, American Journal of Clinical Pathology, 135, p. 97. Copyright M.E. Brecher.
Reprinted with permission.
Using the same 2004 data set as the Brecher and Hay (2011) study, a pilot analysis was
performed using Analysis of Covariance (ANCOVA) and controlling for race, gender and
transfusion history. This sample (n=771) resulted in overall ABO frequencies similar to the
general population (Table 7) and a bimodal distribution of age at the time of death (Figure 2).
The sample consisted of 404 (52.4%) males and 367 (47.6%) females and the majority of the
population had been transfused (76.1%). The racial composition was White (62.6%), Black
(31.4%), Hispanic (3.0%), Asian (0.6%), Native American (0.8%) and unknown (1.6%). The
estimated marginal mean age at the time of death was lowest for the group B patients at 48.0
years and highest for group AB at 62.5 years (Figure 3). Although this could be explained by a
higher prevalence of group B Black persons, the analysis found a statistically significant
difference, F(3, 763), p=0.018, in the age at the time of death among the ABO blood groups
when controlling for race, gender and transfusion history.
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Table 7.
ABO Blood Group Frequencies in 2004 Pilot Data
Phenotype

Frequency

Percentage(%)

O

389

50.5

A

264

34.2

B

92

11.9

AB

26

3.4

Age at Death (years)

Figure 2. Distribution of Age at the Time of Death, Stratified by Decade of Death.
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Figure 3. Estimated Marginal Means of Age at Death for each ABO Blood Group
Most recently a Sicilian population of 38 centenarians and 59 healthy controls were
studied to examine a relationship between ABO and longevity (Vasto et al., 2011). This group
of centenarians (age range 100-107) had no cardiac risk factors or other age-related diseases.
The control group (age range 45-65) was recruited from blood donors and judged to be healthy
on the basis of clinical history and blood tests (complete blood cell count, erythrocyte
sedimentation rate, glucose, urea nitrogen, creatinine, electrolytes, C-reactive protein, liver
function tests, iron, proteins, cholesterol and triglycerides). Samples were genotyped to
determine ABO blood group and Chi Square analysis was used to determine the statistical
significance of differences in ABO of centenarians and controls. Although statistical values
were not reported, the authors concluded that the frequencies of ABO blood groups in the
centenarians and controls did not differ significantly. The inferences are limited due to the
small sample size and regional population, but this study provides an additional disparate
conclusion concerning a relationship among ABO blood groups and longevity and more support
for larger studies to address this question.
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The scientific literature provides a variety of data regarding the relationship of ABO
phenotype with diseases and disorders, as well as overall length of life and survival. Reports of
positive correlations exist for: infectious disease, heart disease, pulmonary function, cancer,
obesity, length of life, survival, and even behavioral traits. It stands to reason that if a particular
blood group provides a protective mechanism against serious illness, then that blood group
should exhibit a longer lifespan. While the overwhelming majority of reports indicate an
association with a particular ABO phenotype, it is important to note the potential for positive
outcome bias. It is possible that studies indicating no association with ABO phenotype are less
likely to be submitted for publication or to be accepted for publication.
Transfusion and Mortality
Since 1981 investigators have provided evidence that transfusion presents risks beyond
infectious disease and incompatibility (Kamper-Jorgensen et al., 2008; Kleinman, Marshall,
AuBuchon, & Patton, 2004; Tynell, Norda, Shanwell, & Bjorkman, 2001; Tynell, Norda,
Montgomery, & Bjorkman, 2005; Vamvakas & Taswell, 1994; Vamvakas & Moore, 1997;
Wallis, Wells, Matthews, & Chapman, 2004; Whyte, 1988). These findings along with the fact
that up to 71 % of hospitalized patients are transfused before they die (Hay, Scanga, & Brecher,
2006), make transfusion history an important factor to consider when examining lifespan or
mortality in any group. Blood transfusions (including all blood components such as red cells,
platelets, and plasma) more than doubled from 1997 to 2007 (Agency for Healthcare Research
and Quality, 2009) and approximately 12 million units of blood are transfused to 3.5 million
patients each year in the United States (Goodnough, Soegiarso, Birkmeyer, & Welch, 1993).
The practice of transfusion is in transition. While the risks of contracting life threatening
infections, such as Human Immunodeficiency Virus (HIV), from blood transfusion are well
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understood, some believe the danger posed by the transfusion itself is more serious (Robinson et
al., 2005). There is a substantial body of evidence demonstrating strong associations between
transfusion and adverse outcomes in a range of clinical settings, including cardiac surgery and
acute coronary syndrome (ACS), where transfusion is administered for reasons other than life
threatening bleeding (Gerber, 2008; Marik & Corwin, 2008; Murphy et al., 2007; Reeves &
Murphy, 2008; Taylor et al., 2006). Some evidence suggests that anemia is not tolerated as well
in critically ill patients (Carson et al., 1996; Hebert et al., 1997), and therefore, prior standard
practice has called for red cell transfusions at a lower hemoglobin threshold to improve oxygen
delivery in an effort to avoid the harmful effects of oxygen debt. However, optimal transfusion
practice in this patient group is being questioned due to reports of adverse outcomes including
postoperative pneumonia, sepsis, immunosuppression, myocardial infarction, heart failure,
stroke, renal failure and mortality. Some adverse reactions such as bacterial contamination
leading to sepsis and incompatibility between the donor and recipient leading to renal failure are
well understood; however, for other adverse outcomes, the etiology is less clear. For example,
heart attack and stroke have been reported (Murphy et al., 2007), but a causal relationship has
not been established. The most notable study to date, a randomized controlled trial of liberal
versus conservative red blood cell use (Hebert et al., 1999), demonstrated that, for patients who
were less acutely ill, mortality was lower in the group receiving fewer transfusions and, for high
risk patients, mortality was similar in the liberal and conservative transfusion groups. The
investigators did not postulate explanations for their findings except to mention that critically ill
patients may be at increased risk for the immunosuppressive (Bordin, Heddle, & Blajchman,
1994; van de Watering et al., 1998) and microcirculatory (Baker, Wilmoth, & Sutton, 1986;
Langenfeld, Livingston, & Machiedo, 1991) complications of red cell transfusion. Future
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endeavors should include randomized trials to investigate if transfusion causes adverse
outcomes, and secondly, to identify patient groups in which the benefit of transfusion outweigh
these risks.
Survival after transfusion. A summary of the literature addressing post-transfusion
survival lends support to including transfusion as an important variable when examining
mortality or lifespan (Table 8). Even though not all of the studies are generalizable to the United
States population or free of bias or historical concerns, the results are consistent in finding
increased mortality among transfused patients. Three population-based analyses of posttransfusion survival in the United States have been published. The first followed a cohort of 802
patients transfused in 1981 in one Midwestern United States county (Vamvakas & Taswell,
1994), and the second followed surgical patients who were transfused perioperatively in 1986
through 1988 in the same county (Vamvakas & Moore, 1997). The third study is an
observational study that used data extracted from a managed care administrative claims database
and is the largest United States study to date addressing post-transfusion survival with a sample
of 6779 patients (Kleinman et al., 2004).
Kleinman and colleagues (2004) reported an overall annual mortality of 31 percent in
year one after transfusion, 14 percent in year two, and 10 percent in each of years three through
five. Compared to earlier work (Vamvakas & Taswell, 1994), these researchers report a seven
percent decreased survival at year one and a 14 percent decreased cumulative survival at year
five (Kleinman et al., 2004). The authors attribute this to the greater percentage of their
population over age 65 and report that transfusion mortality was much higher in recipients older
than age 65. The earlier two studies lack generalizability to a current United States population
due to their timeframe and the changes in transfusion practice over time, lack of representation
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Table 8.
Comparison of Different Studies of Survival After Transfusion
Time after transfusion (%)
Author
Vamvakas
and Taswell
(1994)
KamperJorgensen, et
al. (2008)
Whyte
(1988)
Vamvakas
and Moore
(1997)
Tynell, et al.
(2001)
Wallis, et al.
(2004)
Kleinman, et
al. (2004)
Tynell, et al.
(2005)
Tynell, et al.
(2005)
a

Year of
Transfusion
1981

N
802

1983-2002

1,118,261

1984

Location
US

1 year
76

2 years
70

5 years
60

7 years
48

Denmark and
Sweden

74

NRa

53

NR

367

New Zealand

79

75

NR

NR

1986-1988

1540

US

83

78

67

NR

1993

1734

Sweden

66

58

NR

NR

1994

2899

68

59

47

NR

1995

6779

Northern
England
US

69

60

46

NR

1993

932

Sweden

68

59

45

39

2000

990

Sweden

74

NR

NR

NR

NR = Not reported

from other geographic areas in the United States, and the inclusion of only surgical patients in
the second study. Because all of the study participants studied by Kleinman and colleagues
(2004) were enrolled in managed care, it is possible that this population was healthier than the
populations of the earlier studies. The populations of each of these studies are problematic
because survival rates of transfused patients would be expected to differ between patient groups,
and none of the United States studies to date have sampled the general population.
A fourth United States study examined Medicare beneficiaries with a new
Myelodysplastic Syndrome (MDS) diagnosis in 2003 (Goldberg et al., 2010). Although the
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primary aim of this study was to determine incidence of complications of MDS among Medicare
beneficiaries, the findings regarding survival post-transfusion were striking. A retrospective
review of United States Medicare claims was performed to determine the incidence, clinical and
economic consequences of MDS, focusing on those beneficiaries greater than 65 years old. The
symptoms of MDS reflect peripheral cytopenias and for most patients with MDS, supportive care
with blood transfusions is a requirement of treatment. Compared with the MDS patients who
were not transfused, the MDS patients who received blood transfusions had a greater prevalence
of comorbidities such as cardiac events (82.4% in transfused, 67.1% in nontransfused, p <
0.001), diabetes mellitus (44.4%, 37.1%, p = 0.10), dyspnea (62.9%, 40.4%, p < 0.001), and
infectious diseases (81.0%, 55.7%, p < 0.001). Additionally, the authors noted that although
acute myeloid leukemia developed within 3 years in 9.6% of patients, there was a much higher
transformation among those who had received transfusions (24.6%, p < 0.001). The 3-year
adjusted survival for MDS patients was 60%, significantly lower than for the general Medicare
population (84.7%; hazard ratio, 3.08; p <0.001), and nontransfused patients had a higher 3-yearage-adjusted survival rate than transfused patients (69.0% versus 40.9%). After adjusting for
age, transfusion was associated with an increased risk of death among patients with MDS
(hazard ratio, 2.41; 95% CI, 1.84-3.15; p < 0.001). The authors noted increased rates of
comorbidities, transformation to acute leukemia and a decreased overall survival rate for
transfused MDS patients when compared to nontransfused MDS patients. Some of this effect
could be related to an increased need for transfusion among patients with more advanced disease;
however transfusion dependency identifies patients with MDS at additional risk of shortened
survival.
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Post-transfusion mortality in the United States appears to be similar to European findings
and suggests that data collected during similar timeframes in different developed countries may
be generalizable to other geographical locations. Kamper-Jorgensen and colleagues (2008)
examined short and long-term mortality among transfusion recipients versus the general
population using blood bank databases and administrative data in Denmark and Sweden. This
descriptive study of over one million transfusion recipients provided absolute and relative
survival after transfusion and concluded that survival was poorer in men versus women, and in
all but the 0 to 19 age group, increased age at first transfusion was associated with worse
survival. Absolute mortality was high in the period shortly after transfusion. Standardized
mortality ratios were 17.6 times higher three months post-transfusion. Even 17 years after
transfusion, the data show a 30 percent increase in mortality. Although Kamper-Jorgensen and
colleagues (2008) use mortality data from the general population for comparison, matched
groups with similar baseline characteristics who are not transfused are needed to draw stronger
conclusions regarding causation.
Conclusions concerning the relationship between blood transfusion and an increased risk
of death cannot be drawn from the post-transfusion survival studies conducted to date. Thus far,
studies have been descriptive, not etiologic. However, as suggested by Kamper-Jorgensen
(2008), the poor survival reported after blood transfusion reflects the fact that transfusions are
given to patients who already are at increased risk of dying from trauma, surgeries or serious
illness.
Survival rates of transfused patients are expected to differ between patient groups and
data on survival need to be related to the case mix. Transfusion criteria have changed over time
due to concerns about the blood product supply, the safety of blood products after the emergence
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of HIV, or the demand for more aggressive treatment in elderly patients. Because transfusion
practice could be more aggressive or more conservative depending on timeframe or patient
group, caution should be exercised when making direct comparisons of absolute survival
between studies. Differences in survival could also be explained by the use of different
transfusion triggers, population specific characteristics, variation in transfusion policy or
differences in standards of medical care between countries, between hospitals, or over time. The
strength of these associations across a range of clinical settings suggests that confounding and
bias, the chief limitations of all observational studies, are unlikely to account for all of these
observations.
Cardiovascular disease, transfusion and survival. It is recognized that patients with
cardiovascular disease may be adversely affected by anemia (Jan & Chien, 1977). A
retrospective study of 1958 patients who refused blood transfusion reported an increase in the
risk of death (Carson et al., 1996) with decreasing preoperative hemoglobin concentrations in
patients with cardiovascular disease compared to other patients (Carson et al., 1996). Although
transfusing blood to anemic patients with ischemic heart disease may theoretically increase
oxygen delivery and improve outcomes, there is no definitive evidence to support transfusion. In
fact, studies of patients following cardiovascular surgery and patients in circulatory shock report
no increase in tissue oxygenation with blood transfusion (Casutt et al., 1999; Dietrich, Conrad,
Hebert, Levy, & Romero, 1990; Fortune et al., 1987). Despite consistent findings from
physiological and observational studies regarding the risks of anemia in patients with ischemic
heart disease, there remains limited evidence that blood transfusions increase survival in this
population. Conflicting results have been reported in studies attempting to discern whether
blood transfusions improve outcomes in patients with ischemic heart disease (Hebert et al., 1999;
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Rao et al., 2004; Wu, Rathore, Wang, Radford, & Krumholz, 2001). Small randomized trials
with samples ranging from 25 to 99 patients report no difference in outcomes for groups
randomized to restrictive or conservative transfusion strategies (Bush, Pevec, & Holcroft, 1997;
Fortune et al., 1987; Johnson et al., 1992).
In the largest randomized trial to date, Hebert and colleagues (1999) examined whether a
restrictive transfusion strategy versus a liberal transfusion strategy produced equivalent results in
critically ill patients. This study of 838 patients compared rates of all-cause mortality at 30 days
and severity of organ dysfunction. Thirty day mortality was similar in both groups, but the rates
were lower with the restrictive strategy among patients who were less acutely ill and patients
who were less than 55 years old. Rates were not lower among patients with clinically significant
cardiac disease. The mortality rate during the hospital stay was significantly lower in the
restrictive strategy group. Hebert and colleagues (1999) concluded that the restrictive strategy is
at least as effective as and possibly superior to a liberal transfusion strategy in critically ill
patients, with the possible exception of patients with acute myocardial infarction (MI) and
unstable angina.
In contrast, Wu and colleagues (2001) retrospectively studied 78,974 Medicare
beneficiaries who were hospitalized with a primary diagnosis of acute MI and categorized
patients according to their admission hematocrit level. Only 3680 patients in this sample
received a blood transfusion. The authors used Chi square analysis to evaluate the association
between blood transfusion and 30-day mortality among hematocrit groups and reported that
patients with lower hematocrit values had increased 30-day mortality. Patients were categorized
based on their hematocrit at admission. The investigators found that blood transfusion was
associated with decreased 30-day mortality among the patients with hematocrit values of
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between 5 and 33 percent and with lower short-term mortality among elderly patients with acute
MI if hematocrit was less than or equal to 30 percent at admission. Patients who received a
transfusion despite having a hematocrit greater than 36 percent had a higher risk of death within
30 days than patients with similar hematocrit that were not transfused. When the patients that
died within two days of admission were removed from the data, then transfusion was associated
with lower mortality among patients with hematocrit less than or equal to 30 percent. This study
was among the first to demonstrate that red blood cell transfusion may be beneficial in patients
with acute MI. However, the results are limited by biases. This study suffered from a low rate
of transfusion (4.7%). Additionally, the group of patients that were transfused differed
significantly from the group that was not transfused with regard to clinical presentation and
coexisting factors, and the analysis was not based on the hematocrit value associated with the
transfusion, rather the hematocrit at admission. Wu and colleagues (2001) attempted to account
for survivor bias in a secondary analysis by excluding patients who died within two days of
admission. This eliminated the association between transfusion and improved mortality in
patients with hematocrits between 30 and 33 percent.
Following the results of Wu and colleagues (2001), Rao and colleagues (2004) attempted
to overcome some of these limitations. Rao and colleagues (2004) used detailed prospectively
collected data, focused on a patient population that required more aggressive intervention and
greater exposure to blood products and used more robust statistical techniques to better adjust for
the influence of baseline characteristics and time. The authors reported that transfusions were
not associated with improved survival when nadir hematocrit values were in the range of 20
percent to 25 percent and were clearly associated with worsened outcomes when values were
greater than 30 percent. Rao and colleagues (2004) conclude that transfusion in the setting of
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ACS is associated with higher mortality even after adjustment for other predictive factors and
timing of events. Limitations of this study include a smaller sample (2400 transfused patients)
that would not allow for detection of an overall mortality difference as large as 1 percent, the
potential for unmeasured confounders that could account for increased mortality with
transfusion, and the use of patients enrolled in a clinical trial as they could differ from the
general population.
Although their patient populations differ in age and comorbidities, both Wu and
colleagues and Rao and colleagues (2004) demonstrated that patients who receive red blood cells
at a higher hematocrit level appear to be harmed by transfusion. At hematocrit levels less than
30 percent it is possible that the interpretation given by the authors represents aspects of the true
effects, especially since there are many differences between studies. Wu and colleagues (2001)
derived observations from Medicare claims data from a wide population of elderly patients who
had acute MI, whereas Rao and colleagues (2004) only included younger individuals who
required aggressive interventional management. It is plausible that a higher transfusion
threshold would benefit elderly patients because of the greater degree of diffuse vascular disease,
the presence of additional comorbid illnesses, or the inability to augment cardiac output as a
means of compensation for anemia. Younger patients may derive less benefit from transfusions
because of widespread use of aggressive revascularization procedures, statins, anti-platelet
agents and other therapies.
Most recently, Weightman and colleagues (2009) conducted a prospective observational
study of patients who underwent cardiac surgery. The association between length of survival,
blood products transfused and risk factors for long-term survival at entry to the study were
determined by Cox proportional hazards regression. The authors reported no association
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between transfusion and long-term survival. The sample size (1062) was small compared to
other observational studies and the participants included low-risk cardiac surgery patients. The
authors also included anemia as a risk factor in their analysis. Preoperative anemia is a
predisposing factor for blood transfusion, and it could be argued that any association between
anemia and adverse outcome is actually the result of blood transfusion. In addition, the
investigators stratified the data into four groups based on the number of units transfused. It is
possible that stratification diluted the conclusions and lead to a Type II error. The group without
transfusion was disproportionately large compared to the other three groups, despite an overall
transfusion rate in the study of 57 percent. The authors acknowledge that the study is
inadequately powered. Another difference in this study is the inclusion of plasma, platelets and
cryoprecipitate in equal weight to red cell transfusions. This confounds the analysis and makes
this study different than previous studies. It is unlikely that the impact of acellular blood
components would be identical to that of red cells.
Red cell transfusions are standard practice for many patient groups including critical care,
but there are contradictory views on the risks of anemia and the benefits of transfusion. The
body of evidence indicates various adverse effects including pneumonia, sepsis and mortality in
patients who receive blood transfusion (Gerber, 2008; Marik & Corwin, 2008; Murphy et al.,
2007; Reeves & Murphy, 2008; Taylor et al., 2006). Although an association with transfusion
and overall survival is suggested (Kamper-Jorgensen et al., 2008; Kleinman et al., 2004) ,
contemporary data from a United States population and evidence from randomized trials are
lacking. Many investigators have focused their research question on the survival of patients after
transfusion in the context of ACS (Hebert et al., 1999; Rao et al., 2004; Weightman, Gibbs,
Sheminant, Newman, & Grey, 2009; Wu et al., 2001). The lack of randomized trials and the
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apparent contradictory results from the observational studies leave this topic up to debate. Based
on current studies, it is evident that transfusions in the presence of ACS are rarely beneficial
when the hematocrit level exceeds 30 percent (hemoglobin > 10.0 g/dL) in the absence of acute
blood loss. It is reasonable to conclude that the benefits of transfusion exceed the risks when
hemoglobin concentrations fall below 7.0 g/dL. Between 8.0 and 10.0 g/dL, there remains no
consensus. Randomized controlled trials in different populations of patients with ischemic heart
disease are needed. Information on survival of transfusion recipients is essential if risk-benefit
and cost-effectiveness calculations are to be made.
Life Expectancy in the United States
Because the primary outcome of this research endeavor is length of life or lifespan, it is
important to consider the life expectancy of the pertinent population and how it may differ when
other risk factors (such as gender or race) are included. Life expectancy is a hypothetical
measure that uses current age-specific death rates to predict the future survival of a cohort. This
prediction is necessary as calculating actual life expectancy would be unreasonable due to the
requirement for following a particular cohort until the death of the last survivor. As a measure,
life expectancy is often used to gauge the overall health of a population. Life expectancy is
calculated as the average number of years of life remaining for persons who have attained a
certain age. As a summary measure of mortality, life expectancy represents the average number
of years of life that could be expected if current death rates were to remain constant (Jekel, Katz,
Elmore, & Wild, 2007). Death rates at or above a given age, independent of mortality at younger
ages, are used to predict life expectancy. Changes in life expectancy can be used to help explain
trends in mortality (Caselli, Vallin, & Wunsch, 2006).
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The National Center for Health Statistics provides data on life expectancy in the United
States (Table 9). The United States Life Tables provide data by gender and by race for Whites
and Blacks, but does not further differentiate by race. From 1900 though 2004, life expectancy
at birth increased 29 years for men (to age 75) and 32 years for women (to age 80). Life
expectancy at age 65 also increased during this period rising from 12 to 17 years for men and
from 12 to 20 years for women. In contrast to life expectancy at birth, which increased sharply
early in the 20th century, life expectancy at age 65 improved primarily after mid-century.
Decreased death rates are explained by improved access to health care, advances in medicine,
healthier lifestyles, and better health before age 65. In 2004, life expectancy at birth showed a
disparity among race with 76 years for White males compared with 70 years for Black males and
81 years for White females compared with 76 years for Black females. However, life
expectancy at birth increased more for the Black than for the White population between 1990
and 2004. During this period, the gap in life expectancy between White males and Black males
narrowed from 8 years to 6 years. During the same period, the gap in life expectancy between
White females and Black females decreased from 6 years to 5 years. The gap in life expectancy
between White and Black people at age 65 is narrower than at birth. Between 1990 and 2004, the
difference in life expectancy at age 65 between White males and Black males remained stable at
2 years. In 2004, life expectancy at age 65 was 17 years for White males and 15 years for Black
males. The difference in life expectancy between White and Black females has also been stable
in recent years; in 2004, at age 65, White females and Black females could expect to live an
additional 20 and 19 years, respectively (National Center on Health Statistics, 2007).
Socioeconomic status. Also related to lifespan and virtually all health outcomes in most
countries is socioeconomic status. People with more education or income live longer and
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Table 9.
United States Life Expectancy (in years) by Race and Gender
Male

Female

Total

White

75.7

80.8

78.3

Black

69.5

76.3

73.1

All Races

75.2

80.4

77.8

Note. From “Health, United States, 2007 with Chartbook on Trends on the Health of American,” The National
Center for Health Statistics, 2007, Hyattsville, MD.

experience fewer adverse health events. Racial or ethnic disparities do not simply reflect
differences in income and the likelihood of poor or fair health are seen within each income group
(Robert Wood Johnson Foundation, 2008). Blacks, American Indians, Hispanic Americans,
Pacific Islanders and some Asian-American groups are disproportionately represented among the
more socioeconomically disadvantaged groups in the United States. This reflects a long history
of racial inequality in which race or ethnic origin was legally used to exclude individuals from
employment, educational opportunities and property ownership. Although most explicit uses of
race to demean or exclude people from participation in society have been outlawed, racial
residential segregation persists.
A report from the Robert Wood Johnson Foundation (2008) describes the scope of health
disparities in the United States, specifically how the poor and middle class are less healthy and
how factors in our society contribute to health disparities. In the United States, where education
and income are the most frequently used measures of socioeconomic status, Americans who are
poor and those who have not graduated from high school experience considerably worse health
on average than more affluent or educated Americans. Health differences across income and
education groups are seen in a range of health conditions from the beginning of life to old age.
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Individuals with lower family incomes are more likely to have a chronic disease that limits their
activity. Poor adults are more than three times as likely as affluent adults to report activity
limitation due to chronic illness. Lower income also means higher rates of type 2 diabetes. Poor
adults are twice as likely as affluent adults to have diabetes, which is a major cause of severe
illness, disability and premature death. Similar patterns are seen for coronary heart disease. The
rate of coronary heart disease, the leading cause of death in the United States, is nearly 50
percent higher among poor adults than among the most affluent adults (Robert Wood Johnson
Foundation, 2008).
In one study, researchers at the United States Centers for Disease Control and Prevention
(CDC) estimated that 38 percent of the two-fold excess mortality among Black adults compared
with Whites in the United States was related to differences in income (Otten, Teutsch,
Williamson, & Marks, 1990). The role of genetic differences in health disparities has been
debated, but scientific sources have concluded that race is primarily a social, not biological,
construct (American Association of Anthropology, 1998; American Association of Physical
Anthropologists, 1996).
It has long been recognized that those of lower socioeconomic status have higher
mortality in the United States (Kitagawa & Haser, 1973). Differential socioeconomic status is
assumed to be the cause of large differences in healthy life expectancy for racial groups in the
United States (Crimmins, Saito, & Ingegneri, 1989; Hayward & Heron, 1999; Sullivan, 1971;
Williams & Collins, 1995). At older ages, the reported pattern of differences in healthy life
expectancy by race varies somewhat (Branch et al., 1991; Guralnik, Land, Blazer, Fillenbaum, &
Branch, 1993; Manton & Stallard, 1991). In a national sample of age 70 and over, African
American and White total life expectancy was quite similar, while White healthy life expectancy

65

exceeded African American healthy life expectancy (Crimmins, Hayward, & Saito, 1996).
However, in a North Carolina sample, African American life expectancy above age 75 has been
found to exceed White values (Guralnik et al., 1993; Land, Guralnik, & Blazer, 1994).
Crimmins and Saito’s (2001) report examined differences in healthy life expectancy, which
summarizes the combined effects of different levels of mortality and morbidity on the overall
length of healthy life. It provides a summary indicator of the total health impact of differences in
socioeconomic wellbeing. This report examined healthy (disability free) life expectancy by
gender and education for Whites and African Americans in the United States at three dates
(1970, 1980 and 1990). The authors reported large racial and educational differences in healthy
life expectancy at each date (Crimmins & Saito, 2001). They reported that the differences by
education in healthy life expectancy are even larger than differences in total life expectancy.
Arthur and colleagues (2008) sought to determine whether race was associated with risk of inhospital death after injury. They found that relative to injured White patients, Black and Asian
patients had a higher risk of death (1.5% vs. 2.1%). Other racial/ethnic groups showed no
significant mortality difference from White patients. The authors concluded that Black and
Asian patients have a higher risk of death after injury than White patients (Arthur, Hedges,
Newgard, Diggs, & Mullins, 2008).
Summary
The particular problem addressed by this project is whether individuals belonging to
different ABO blood groups differ in their length of life or lifespan. The question is not a new
one. As long ago as 1921, investigators examined associations of ABO blood groups with peptic
ulcer, pernicious anemia and other malignant diseases (Buchanan & Highley, 1921). Interest
decreased for the next 30 years and then Aird and colleagues (1953) published a paper showing
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that there was a striking relationship between group A and carcinoma of the stomach. Since this
time, a great deal of literature has accumulated.
There are some undeniable associations of blood groups with disease. Blood group
antibodies can cause hemolytic transfusion reactions, hemolytic disease of the newborn and
autoimmune hemolytic anemia, graft rejection and spontaneous abortion. What is more open to
debate is whether the many statistical associations with other diseases have clinical significance,
and whether blood group antigens have a biologic role. Much progress has been made since the
early reports of statistical associations of ABO blood groups and various diseases. Some of the
seemingly coincidental associations now have a scientific basis. As Garratty (2000) suggests,
even though blood groups were discovered in the process of trying to successfully transfuse
blood, “common sense should dictate that blood group antigens and antibodies are not there only
to give us problems in this unnatural process.”
ABO blood group antigens, first identified on RBCs, are now known to be important as
receptors and ligands for microbes and immunologically important proteins. Increasing
evidence indicates that some blood group antigens may play a biologic role, but that role may not
be directly related to the RBC (Garratty, 2000). Immunohematologists labeled these chemical
structures as “blood group” antigens because they caused problems in transfusing blood.
However, as Garratty (2000) proposes, it should be remembered that the anti-A and anti-B are
naturally occurring antibodies probably because they are antibacterial antibodies that cross-react
with RBCs. Contemporary findings in the fields of membrane chemistry and molecular biology
add some rationale to some of the earlier statistical associations found. However, it remains
unclear if blood group antigens play a biological role or if there is an association with ABO
blood group and lifespan.
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It is clear from the abundance of published works on the association between ABO
phenotype and a myriad of human conditions that it is significant and ubiquitous. Researchers
have come to conflicting conclusions on relationships and it is evident that further studies must
be conducted. Since ABO blood group is a characteristic of all people, this study has the
potential to provide information about the human race, including correlations of ABO blood
groups with diseases and disorders. Although environmental characteristics may influence
length of life and proliferation of a particular blood group, the fact that ABO blood group is
entirely a genetic component makes this topic of great importance and globally relevant.
The geographic inheritance patterns of ABO blood groups and how ABO blood group
relates to environmental factors to improve health or escape illness has been questioned almost
since the ABO blood system was first discovered. This project will answer the question, is there
a relationship between ABO blood group and lifespan in a hospitalized Southeastern United
States population? It is relevant because existing evidence regarding a relationship among ABO
blood groups and lifespan is slight and studies are contradictory. This non-experimental,
retrospective study will have a target population of all patients who died at three tertiary care
centers over a one-year period. A statistical model will be employed to determine length of life
across ABO blood groups and ANCOVA will be used to test for differences in the mean lifespan
of patients. This investigation of the overall association of ABO blood group and lifespan from
a macro-perspective in a large population and controlling for covariates such as race and gender
is a first step towards determining if blood group antigens have a functional role. A broad scale
study of this magnitude has yet to be performed in the United States. Consequently, the results
of this study combined with the advances in molecular genetics and cellular biochemistry will

68

allow us to further investigate biochemical mechanisms responsible for longer life spans for
persons of a particular blood group.
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Chapter Three: Methods

The details of the research design are provided in this chapter and include: identification
of the methodology, variables, population and sample, data collection procedures and analytical
procedures. Because previous research efforts suggest that certain ABO blood groups are linked
to protection from various diseases or disorders (Aird, Bentall, & Roberts, 1953; Brecher & Hay,
2011; Gonzalez Ordonez, Medina Rodriguez, Martin, Alvarez, & Coto, 1999; Kingsbury, 1971;
Shimizu et al., 2004; Suadicani, Hein, & Gyntelberg, 2007), it stands to reason that individuals
of a particular group will demonstrate a longer lifespan. A particular ABO blood group may
contribute to length of life via biomedical mechanisms favorable for surviving or eluding serious
disease. A vast number of research endeavors point to an association of ABO blood groups with
specific diseases, but the biological role of ABO antigens remains uncertain. Fewer studies have
examined an association with ABO blood groups and lifespan or longevity, (Brecher & Hay,
2011; Hong et al., 2006; Shimizu et al., 2004; Vasto et al., 2011) and the results are inconsistent.
The proposed project is the largest to date to examine the relationship between ABO blood group
and lifespan from a macro-perspective and includes covariates not previously studied.
Unquestionable associations of disease with blood group include hemolytic transfusion
reactions, hemolytic disease of the newborn, autoimmune hemolytic anemia and graft rejection
(Roback, Grossman, Harris, & Hillyer, 2011). Statistical associations have been reported with
ABO blood group and malignancy, thrombosis, peptic ulcers, bleeding and infectious disease
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(Aird et al., 1953; Aird, Bentall, Mehigan, & Roberts, 1954; Hein, Suadicani, & Gyntelberg,
1998; Robert et al., 2000; Shimazu, Shimaoka, Sugimoto, Taenaka, & Hasegawa, 2000;
Suadicani et al., 2007). The biological role of ABO antigens remains uncertain. It has been
proposed that the polymorphic genes of the ABO blood group provide the diversity needed to
survive changing environmental conditions and evolving pathogens (Marionneau et al., 2001).
Although the statistical associations with ABO blood group and disease are prevalent in the
literature, fewer studies have examined an association with ABO blood group and overall
survival or longevity. Shimizu and colleagues (2004) compared frequencies of ABO blood
groups in centenarians in their Tokyo population, and Brecher and Hay (2011) collected data on
the ABO blood groups of a population of patients who died in a United States tertiary care
center. While Shimizu and colleagues found group B more frequent in the centenarian
population, the prevalence of group B declined with age in the United States population. Thus,
the findings of Brecher and Hay suggest that group B is not a marker for longevity. Both of
these studies conflict with a report from a Sicilian population that found no difference in ABO
blood groups with regard to longevity (Vasto et al., 2011). Because the existing evidence is
scarce and the results are contradictory, this project further examined the relationship between
ABO blood group and lifespan in a Southeastern United States population. By assessing a larger
population and controlling for more variables, this study provided more robust data for analysis
and a foundation for future studies to investigate this question at the molecular level or from an
aspect of glyconomics (the study of sugar-modifications to proteins that affect the structure and
function of blood group antigens).
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Research Design
The proposed project answered the question, “Among patients who die in a hospital, is
there a significant relationship between ABO blood group and lifespan?” An epidemiological
approach was used to arrive at a conclusion using a retrospective study and analysis of
covariance techniques. The sample population included all patients who expired at three tertiary
care centers over a one-year period. If a significant relationship exists between ABO blood
group and the lifespan of patients, as determined by age at death, in a tertiary care center setting,
this study design would allow for this determination. ANCOVA was used to determine if a
significant difference in mean age at death exists among the ABO blood groups of this
population. The study was based on the following assumptions: (1) the data needed could be
collected from a retrospective review of electronic blood bank and administrative records, (2) the
data provided by the clinical records was accurate, and (3) by using ANCOVA techniques, it
would be possible to illustrate that ABO blood group is a marker for lifespan.
The design used for this study was a non-experimental, retrospective study with no
control group. In this non-experimental design, a control group was not necessary since the
ANCOVA analysis would statistically equate the groups on given variables. Within the study
population, ANCOVA was used to compare the ABO blood groups: A, B, O and AB, which
represented the independent variable (IV). Lifespan (measured as age at the time of death) was
the dependent variable (DV) and the statistical analysis adjusted the means of the DV such that
all study subjects were equal with respect to covariates (CV). Differences among subjects on
CVs were removed so that the only differences that remained were related to the effects of the
ABO blood group variable.
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This project employed a retrospective review of electronic clinical records for a one-year
period from three tertiary care centers: Wake Forest University Baptist Medical Center
(WFUBMC), Virginia Commonwealth University Medical Center (VCUMC) and the University
of North Carolina Hospitals (UNCH). The project was an observational epidemiologic study that
required no intervention. Due to the nature of the study, IVs could not be manipulated; and
therefore, the non-experimental design was necessary. The design prevented the investigator
from assigning patients to conditions or using randomization. The investigator provided
descriptive statistics and attempted to establish comparability among the different ABO blood
groups and among the different sites of collection.
Variables. ABO blood group and age served as IV and DV, respectively. Age
represented the age at the time of death and was recorded in years as a whole number. Gender,
race, transfusion history and site of data collection served as CVs. Gender was defined and
recorded as male (1) or female (2). Race was defined according to the existing options in the
hospital information systems and was recorded as: White (1), Black (2), Native American (3),
Hispanic (4), Asian (5), Other (6) or Unknown (7). The “Other” category included patients who
identified themselves as a racial group not listed as an option. The “Unknown” category
included patients who did not have a race indicated in their medical record. Transfusion history
was recorded as a dichotomous variable (yes/no) and was defined as exposure to RBCs during
the year prior to the patient’s death at the facility where the patient died. It was expected that
the patient populations from the three sites (WFUBMC, UNCH, or VCUMC) would be similar;
however, site of collection was included as a CV to rule out a proxy geographic effect or
differences in hospital practice.
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Research questions. Initially, the prevalence of the ABO blood groups were determined
by calculating the percentage of each blood group in the sample population. If a relationship
between ABO blood group and lifespan exists, the prevalence of ABO blood groups in the
sample population may differ when compared to the known proportions of ABO blood groups in
the United States population (Garratty, Glynn, & McEntire, 2004). Secondly, mean lifespan (as
measured by mean age at the time of death) was calculated for each ABO blood group and
compared to the other ABO blood groups. The sample was also stratified by race, gender and
site in order to observe descriptive statistics by ABO blood group. An ANOVA (Analysis of
Variance) was performed to examine differences in the age of death among the ABO blood
groups, and ANCOVA analysis was used to determine if CV effects existed and if age at death
was related to ABO blood group when the sample was adjusted for CVs. The total analysis
answered the question, “Does lifespan, as defined by age at death, differ with ABO blood group
in a hospital population when controlling for race, gender, transfusion history or site?” The
statistical analysis will test the null hypothesis that age at the time of death does not differ with
ABO blood group after adjusting for race, gender, transfusion history and site.
Description of sites. VCUMC (Richmond, Virginia), UNCH (Chapel Hill, North
Carolina), and WFUBMC (Winston-Salem, North Carolina) are all academic medical centers in
the Southeast United States and each consists of an integrated network of hospitals, clinics and
health sciences schools. While one facility or a smaller geographic region could have been
chosen to minimize confounding variables, this would limit the generalizability of the results.
Tertiary care centers were chosen in order to provide the largest sample sizes and most diverse
patient populations that reflected the population of the region. Each of the three centers is a
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teaching facility, and all are categorized as large hospitals (US Department of Health and Human
Services, 2008) based on bed sizes of 708 (UNCH), 779 (VCUMC) and 872 (WFUBMC).
All three facilities serve as regional referral centers in Virginia or North Carolina and
care for patients in almost every county of their state. Each center is an integrated health care
system that operates acute care, rehabilitation and long-term care beds, outpatient services, and
community health and information centers. The centers have outreach activities throughout the
region, including satellite clinics, health fairs and consulting services. They provide a continuum
of care that includes primary care centers, outpatient rehabilitation, dialysis centers, home health
care and long-term nursing centers.
Population and sample. The target population included all patients who expired at the
three tertiary care centers during a one-year period (January 1, 2010 through December 31,
2010). Only stillborn infants and those patients with missing data were excluded from analysis.
All variables were screened for missing values and their distributions were evaluated. The
sample was inclusive of all patients who died within the project timeframe; thus, producing a
non-random, convenience sample. This seemed appropriate since the goal was to examine the
lifespan of all patients with respect to a particular ABO blood group.
Sample size and power. Previous research indicated that 85% of patients who expire in
a tertiary care center have blood types in their medical record (Brecher & Hay, 2011).
Therefore, it was anticipated that 15% of deceased patients would be excluded from the sample
because of missing data. Using 2004 data from the facility with the smallest bed size (UNCH),
this sampling method resulted in 772 patients (Brecher & Hay, 2011). Therefore, the estimated
sample size for this project, using three facilities of about equal size and offering very similar
services was (772 patients x 3 centers) 2,316 patients.
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For comparative questions, sample size requirements are determined based on the effect
size desired at a usual power of 0.80. If power is set at 0.80, then each ABO blood group needed
60 patients in order to detect a medium effect size (0.50) (Cohen, 1988). Known population
statistics for ABO blood groups (Garratty et al., 2004) were used to predict the number of
patients of each blood group in the expected sample of 2,316 patients. Blood groups B and AB
are the rarest of the blood groups, making up 11% and 4%, respectively, of the United States
population (Garratty et al., 2004). Using these statistics and the study’s total sample size, an
estimate of the number of B and AB patients in the sample was 255 and 93, respectively. With
an anticipated sample of 93 in the rarest blood group, this design was predicted to meet the
sample requirements.
Data collection procedures. The data used for this project were extracted from the
hospital and blood bank information systems at three tertiary care centers: VCUMC, WFUBMC
and UNCH. Data were collated and synthesized in a comprehensive data base by the principal
investigator. The collection process and project timeline are summarized in Figure 4 and Table
10.
The following project liaisons were established at each of the three tertiary care centers to
facilitate access to the data required: Dr. Yara Park (UNCH), Dr. Emmanuel Fadeyi
(WFUBMC), and Dr. Susan Roseff (VCUMC). These project liaisons formed a support team,
which worked with the principle investigator to prepare Institutional Review Board (IRB)
proposals and manage the data acquisition keeping this consistent among all centers.
Additionally, project liaisons helped to expedite access to any other required personnel at each
facility. Once IRB approval was received, hospital records staff supplied a list of all patients
who expired at the three institutions from January 1, 2010 through December 31, 2010. The
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Met with project liaisons and submitted IRB proposals at each site.

Received IRB approval and began data acquisition at each site.

VCUMC:
Obtained patient list
containing medical
record number, date of
birth, date of death,
gender and race.

WFUBMC:
Obtained patient
list containing all
variables.

UNCH:
Obtained patient list
containing medical
record number, date
of birth, date of
death and gender.

Queried blood bank
information system
for ABO blood
group, race and
RBC transfusion
history.

Queried blood bank
information system for
ABO blood group and
RBC transfusion
history.

Deidentified data and combined data from
all sites into one comprehensive database.

Performed data analysis.

Figure 4. Data Collection Flowchart
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Table 10.
Project Timeline

Project Activities
Liaison meetings.
Prepared
management plans.
Prepared IRB
proposals for 3 sites.
Submitted IRB
proposals.
Received IRB
approval.
Requested access to
information systems.

1-4

Months
5-8
9-12 13-16
Planning and Preparation

17-20

21-24

25-28

X
X
X
X
X
(WFUBMC,
(VCUMC)
UNCH)
X

X

Data Collection and Analysis
Prepared
comprehensive
database.
Implemented project
plans. Begin data
collection.
Ongoing data
collection. Received
electronic files.
Ongoing data
collection. Retrieved
ABO blood groups.
Ongoing entry of data
into comprehensive
database.
Data analysis.

X

X

X

X

X

X

X

X

X

X
X

X

Conclusions
Prepared written
results and
discussion.

X

UNCH data required another request to access protected health information for research purposes
from the medical records department. The types of information obtained from each facility on
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the initial list of deceased patients differed among sites and is summarized in Table 11.
WFUBMC supplied the comprehensive spreadsheet which included all the data needed for the
study (date of birth, date of death, race, gender, ABO blood group and RBC transfusion history.
Once the initial lists were received, the blood bank information systems at UNCH and VCUMC
were used to query and record any other data. UNCH data was collected on site at UNCH and
VCUMC data was queried remotely. Once the data collection was complete, the patient
information was de-identified.
Table 11.
Initial Data Received from Each Site
Variable

Site
WFUBMC
VCUMC
UNCH

Date of
Birth




Date of
Death




Gender




Race




ABO
Blood
Group




Transfusion
History




The ABO blood groups, race and transfusion histories which were queried from VCUMC
and UNCH were entered in a comprehensive database using Microsoft Excel 2010 alongside the
corresponding data. The raw data and comprehensive database were stored on the principle
investigator’s laptop computer with security enabled. The data was backed up on a single
secured flash drive. Both the computer and the flash drive were stored in a locked file cabinet in
the principle investigator’s office when not in use. Once all data was collected and entered into
the single database, statistical analysis was performed using ANCOVA. Data analysis used the
information directly from this database and SPSS 21.0 software.
Data analysis. Because ANCOVA is an extension of ANOVA, an initial description of
ANOVA is provided. The primary purpose of ANOVA is to test for differences between means
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of two groups for statistical significance (Tabachnick & Fidell, 2007). When comparing two
means, ANOVA will give the same results as the t test. When there are three or more levels for a
nominal variable (as in the case of ABO blood groups), a simple approach is to run a series of t
tests between all pairs of levels. However, the number of t tests (pairwise comparisons) will
increase geometrically as a function of the number of groups leading to an increased probability
of committing a type I error. A more powerful approach is to analyze all the data at once using
ANOVA. The model is the same, but the test statistic is the F ratio. ANOVA puts all the data
into one number (F) and provides one p value for the null hypothesis.
In ANOVA, to test for statistical difference between means, the variances are compared.
Variance is computed as the sum of squared deviations from the overall mean, divided by n-1
(sample size minus one) (Tabachnick & Fidell, 2007). Given a certain n, the variance is a
function of the sums of squares (SS). Variances can be partitioned. For example, the total SS
can be partitioned into the SS due to within-group variability and the variability due to
differences between means of two groups. The within-group variability is referred to as error
variance (SS Error). This term denotes the error that cannot be readily explained or accounted for
it in the design of the study. However, the variance due to differences between means (SS
Effect) of the groups can be explained by group membership.
Significance testing is based on a comparison of the variance due to the between-groups
variability (called Mean Square Effect, or MSeffect) and with the within-group variability (called
Mean Square Error, or MSerror) (Tabachnick & Fidell, 2007). Under the null hypothesis (that no
mean differences exist between groups in the population), some minor random fluctuation in the
means for the two groups are expected when taking small samples. Therefore, under the null
hypothesis, the variance estimated based on within-group variability should be approximately the
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same as the variance due to between-groups variability. The two estimates of variance are
compared via the F test, which tests whether the ratio of the two variance estimates is
significantly greater than 1. Therefore, in ANOVA, total variance is partitioned into the
component that is due to true random error (in other words, within-group SS) and the
components that are due to differences between means. These latter variance components are
then tested for statistical significance. If significant, the null hypothesis that there are no
differences between means is rejected and the alternative hypothesis that the means (in the
population) are different from each other is accepted.
ANCOVA is similar to ANOVA, but allows for the addition of adjustment of the
differences associated with one or more CVs. The main effects and interactions of IVs are
assessed after DV scores are controlled for the effects of one or more of the CVs (Tabachnick &
Fidell, 2007). As described by Tabachnick and Fidell (2007), ANCOVA could be used for two
purposes in this project: (1) to increase sensitivity of the test of main effects and interactions by
reducing the error term, and (2) to adjust the means on the DV themselves to what they would be
if all subjects scored equally on the CVs. The second use of ANCOVA occurs commonly in
nonexperimental situations, as in the present study, when subjects cannot be randomly assigned
to treatments or groups. In this case, ANCOVA is used as a statistical matching procedure to
adjust group means to what they would be if all subjects scored identically on the CV(s)
(Tabachnick & Fidell, 2007). The differences between subjects on CVs are removed so that they
only differences that remain are related to the effects of the IVs.
With ANCOVA, the focus becomes one of determining the effects of study factors on the
DV adjusted for the presence of the CVs in the model. In ANCOVA, validity is achieved by
adjusting for confounding variables, and therefore, obtaining an estimate of association that
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would have been distorted if the CV(s) of interest had been ignored in the analysis. In the
ANCOVA model, it is assumed that there is no interaction of CVs with study variables, although
this assumption must be assessed in the analysis.
ANCOVA procedures are the same as ANOVA in that variance in scores is partitioned
into variance due to differences among groups and variance due to differences within groups
(Tabachnick & Fidell, 2007). Variance is partitioned by summing and squaring differences
between scores and various means. The total sum of squared differences between scores on the
DV and the grand (overall) mean is partitioned into two components: sum of squared differences
between group means and the grand mean; and sum of squared differences between individual
scores and their respective group means (error). In ANCOVA there are two additional partitions.
First the differences between CV scores and their grand mean are partitioned into between- and
within-groups sums of squares. Similarly, the covariance (the linear relationship between the
DV and CV) is partitioned into sums of products associated with covariance between groups and
sums of products associated with covariance within groups. This results in estimates of variance
attributable to different sources: main effects of IVs, interactions among IVs, and error. Ratios
of variances are used for tests of hypotheses about the effects of IVs on the DV. The difference
between ANCOVA and ANOVA is that in ANCOVA, the regression of one or more CVs on the
DV is estimated first (Tabachnick & Fidell, 2007). Subsequently, DV scores and means are
adjusted to remove the linear effects of the CV(s) before analysis of variance is performed on
these adjusted values. When a main effect is associated with a DV, then the next step is to
quantitate the amount of variance in the adjusted DV that is attributed to the IV. This is referred
to as effect size and is assessed by calculating the ratio of group sums of squares to group sums
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of squares plus error sums of squares or, partial η2 (partial eta squared) (Tabachnick & Fidell,
2007).
This project examined ABO group differences in length of life where age at the time of
death was the measure of lifespan. The four ABO blood groups (A, B, O and AB) formed the
IV. Three variables expected to vary with lifespan were gender, race and RBC transfusion
history and were added to the analysis as CVs. A fourth CV that was considered was site since
subjects will come from three different tertiary care centers. The statistical analysis tested the
null hypothesis that lifespan does not differ with ABO blood group after adjusting for gender,
race, transfusion history and site. Due to the non-experimental nature, this analysis did not allow
for the implication that a greater lifespan is caused by one or more ABO blood groups. Instead,
the results provide descriptive model building and enhanced prediction of the DV. Because
similar data from 2004 reflected a bimodal distribution of age at the time of death (with one peak
in the lowest age group and one peak around 51-60 years), it was predicted that examination of
subgroups might be necessary. For example, one would expect that the disease processes or
reasons for death in the lowest age group differ from those in the older age groups. Therefore,
since the 2010 data from this study produced a bimodal curve, the data were also analyzed
without the lowest age group included. Additionally, any differences between the 2004 and 2010
findings were further examined descriptively and by site.
In this project, ANCOVA was used to test for differences in the mean lifespans. The DV
was age at the time of death, or lifespan. IVs were the four blood groups. In order to control for
the effects of race, gender, site and transfusion history, these four variables were treated as CVs.
ANCOVA is an extension of analysis of variance in which the main effects and interactions of
IVs are assessed after DV scores are adjusted for differences associated with one or more CVs
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(Tabachnick & Fidell, 2007). With ANCOVA, a more precise look at the IV – DV relationship
after removal of the effect of CV(s) was obtained.
The optimal set of CVs was considered since several were available. If too many CVs
are included in an ANCOVA and they are correlated with each other, a “point of diminishing
returns in adjustment of the DV is reached” (Tabachnick & Fidell, 2007, p. 211-212). Power is
decreased because numerous correlated CVs subtract degrees of freedom from the error term but
do not remove corresponding sums of squares for error. Using the statistical analysis, a small set
of CVs can be identified which are uncorrelated with each other but correlated with the DV.
Theoretically, selection should be done by choosing CVs that adjust the DV for predictable but
undesirable sources of variability. It may be possible to pick the CVs on theoretical grounds or
on the basis of knowledge of the literature regarding important sources of variability that should
be controlled. If theory is unavailable or the literature is insufficient to suggest important
sources of variability in the DV, the statistical results can be used to select CVs. If the sample
size is large and power adequate, it may still be worthwhile to find a small set of CVs for the
sake of parsimony (in other words, the least complex explanation) (Tabachnick & Fidell, 2007).
When choosing CVs, all CVs should be correlated with the DV and none should be
substantially correlated with each other. If they are, they do not add significantly to the
reduction of error and can cause computational difficulties such as multicollinearity. The goal is
to obtain the maximum adjustment of the DV with minimum loss of degrees of freedom of the
error term since each CV costs 1 degree of freedom for error. When there is substantial
correlation between the CV and the DV, the gain in terms of power often offsets the loss of
power due to reduced degrees of freedom. The utility of each CV is established by using
significance tests to assess their value in adjusting the DV. Multiple CVs enter the equation as a
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set and within the set, each CV is evaluated as if it entered the equation last. Overlapping
variability with other CVs is eliminated so that only the unique relationship between a particular
CV and the DV is assessed (Tabachnick & Fidell, 2007). In addition to the significance levels
for each CV, correlations between each CV and the DV and correlations among CVs are used to
interpret the worth of CVs. As further runs are made, CVs are eliminated resulting in a small set
of valuable CVs. The analysis with the smallest set of CVs will be reported, but mention will be
made in the Results section of the discarded CV(s) and the fact that the pattern of results did not
change when they were eliminated.
The statistical research question addressed was, are mean differences among ABO blood
groups on the adjusted DV (lifespan) likely to have occurred by chance? Specifically, the
analysis answered the question, is lifespan affected by ABO blood group, after holding constant
race, gender, site and transfusion site? The statistical test did not ensure that changes in the DV
were caused by the IV. The inference in causality is a logical rather than statistical problem that
depends on the manner in which subjects are assigned to levels of the IV(s), manipulation of
levels of the IV(s) by the researcher, and the controls used in the research. Because the IV and
CVs used in the project could not be manipulated, inference depended on the controls used and
the rigor of the research design.
ANCOVA has been used successfully in many nonexperimental studies. For example,
Brambilla and colleagues (2003) examined differences in a nonexperimental study of amygdala
volumes of 24 adults diagnosed with bipolar disorder and 36 adults without bipolar disorder.
Amygdala volumes were measured blindly as the DV. Bipolar disorder status was the IV and
the authors included age, gender and intracranial volume (ICV) as CVs. Bipolar patients had
significantly larger left amygdala volumes compared with controls (mean volumes+/-SD =
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2.57+/-0.69 vs. 2.17+/-0.58 mL, respectively; age, gender, ICV as CVs; F = 4.42, df = 1/55, p =
0.04). The volumes of the other temporal lobe structures did not differ significantly between the
two groups (age, gender, and ICV as CVs, p > 0.05) (Brambilla et al., 2003). Additionally,
serum cholesterol studies were examined in violent and non-violent female suicide attempters
(Vevera, Zukov, Morcinek, & Papezova, 2003). ANCOVA with age as the CV was used to
analyze differences in cholesterol levels in groups according to violence. The three groups were
women with a history of violent suicide attempts, women with a history of non-violent suicide
attempts and a non-suicidal comparison group. Violence was found to be a significant factor (p
= 0.016). The Scheffé test was used as a post-hoc test to compare high violence suicide subjects,
low violence suicide subjects and the control group. Scheffé tests revealed a significant
difference (p = 0.011) between the group of violent and non-violent suicide attempters and
between the violent suicide attempters and the control group. A statistically significant
difference was not found between the non-violent and comparison group. The authors concluded
that patients with a violent suicidal attempt have significantly lower cholesterol levels than
patients with non-violent attempts and the control subjects.
Data screening procedures. After data collection and entry and prior to data analysis,
the data was screened for accuracy with which the data were entered into the appropriate fields
and any other factors that could produce distorted correlations. Univariate descriptive statistics
were inspected for accuracy, plausible means and standard deviations, and univariate outliers.
Stillborn infants and any patients with missing variables were eliminated from the study.
Because the data set was large, this did not pose a problem (Tabachnick & Fidell, 2007). The fit
between the data and the assumptions of the method was also assessed. Pairwise plots of the DV
and CVs were checked for nonlinearity and heteroscedasticity.
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Descriptive statistics were used to examine any missing data or extreme cases and their
distribution was evaluated to ensure that they do not unduly influence or distort results.
Nonnormal variables and univariate outliers were identified by checking for skewness and
kurtosis. Because the assumption of normality applies to the sampling distribution of means and
not raw scores, skewness by itself did not pose a problem. With the large sample size and the
use of two-tailed tests, normality of sampling distributions of means was anticipated (Tabachnick
& Fidell, 2007). Transformations of variables were considered to bring them into compliance
with the requirements of the statistical procedure, but were not needed. Identification of
multivariate outliers was conducted and variables were evaluated for multicollinearity and
singularity. The four CVs (race, gender, transfusion history and site), were assumed to be
reasonably consistent in reporting. Therefore, an adjustment in ANCOVA for unreliability of the
CVs was not required.
Descriptive statistics were used to illustrate prevalence of the ABO blood groups in the
study population as well as frequency of races, gender, transfusion history and the sample size at
each of the three sites. It was expected that the populations at the collection site would be
similar. Even if geographic locale had produced a difference in racial makeup, including race as
a covariate would account for this dissimilarity. A discussion of the statistical analysis plan
follows and is summarized in Figure 5.
Major analysis. The major analysis included main effects and effect sizes for all effects.
Tests of interactions among IVs were not appropriate because the project contained only one IV,
ABO blood group. For example, by evaluating main effects using the F statistic, one can test the
null hypothesis that ABO blood group has no systematic effect on lifespan, thus determine if the
association of the observed changes in lifespan and the IV is larger than expected through
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Figure 5. Summary of Plan for Statistical Analysis
random fluctuations occurring by chance. The procedures answered this question by testing the
null hypothesis that ABO blood group has no systematic effect on lifespan. Since there are more
than two categories of the IV, any finding of statistically significant effects would prompt an
investigation of the nature of the differences. This is because the omnibus F test of a main effect
gives no information as to which means are significantly different from which other means
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(Tabachnick & Fidell, 2007). For example, it would be important to identify which ABO blood
groups differ significantly from each other in post hoc analysis using additional statistical
methods, such as the Scheffé test.
Additional analyses. The plan for additional analyses included the evaluation of CV
effects, evaluation of intercorrelations, appropriate post hoc comparisons (such as Scheffé test
for pairwise comparisons), and unadjusted marginal and/or cell means. ANCOVA is based on a
linear regression between CVs and the DV; however, there is no guarantee that the regression is
statistically significant (Tabachnick & Fidell, 2007). The regression should be evaluated
statistically by testing the CVs as a source of variance in DV scores. For example, this analysis
answered the question: to what extent is it possible to predict lifespan from ABO blood group,
ignoring the effect of race? With multiple CVs, all CVs enter the multiple regression equation at
once. Within the set of CVs, the significance of each CV is assessed as if it entered the equation
last; only the unique relationship between the CV and the DV is tested for significance after
overlapping variability with the other CVs, in their relationship with the DV, is removed. Thus,
although a CV may be significantly correlated with the DV when considered individually, it may
add no significant adjustment to the DV when considered last. When interpreting the utility of a
CV, it is necessary to consider correlations among CVs, correlations between each CV and the
DV and significance levels for each CV.
If the main effect of ABO blood group is reliably associated with changes in lifespan, the
next step in the analysis would be to determine the amount of variance in the adjusted DV scores
that is associated with the IV. Effect sizes (assessed using partial η2) and their confidence
intervals would be determined along with parameter estimates. Importance is usually assessed as
the percentage of variance in the DV that is associated with the IV. If main effects were
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statistically significant, estimated population parameters (adjusted mean and standard deviation
or confidence interval) for each ABO blood group would be calculated. For example, if there is
a main effect for ABO blood group, then what is the average adjusted lifespan in each of the
ABO blood groups?
Because of the bimodal distribution in the 2004 pilot data, planned analyses also included
conducting ANCOVA on the younger and older populations. Additionally, any discrepant
results were further examined using descriptive statistics, t tests to compare means and Chi
Square analysis to compare frequencies.
Validity and reliability of data. Overall, the variables were easily quantifiable and had
face, content, criterion and construct validity, as well as reliability. Since existing databases
were used (the hospital and blood bank information systems), we can anticipate that the same
information would be extracted upon multiple attempts. However, because three different sites
and information systems were used, it is possible that the policies for coding race at each site
were different and could vary among hospital staff and the information available at the time of
admission. Since the information was received or queried electronically, the potential for human
error was minimized. It is possible that different researchers could extract data from different
places in a database and have the potential to make errors as well. However, a single
investigator was responsible for managing the data and developing the comprehensive database.
Summary
This non-experimental, retrospective study examined ABO blood group and lifespan in a
Southeastern United States hospital population. Lifespan across ABO blood groups was
determined by examining age at the time of death and ANCOVA was used to test for differences
in the mean lifespans of patients based on ABO blood group. Gender, race, transfusion history
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and site entered the analysis as CVs to control for any of their influences on lifespan. By using
hospital data from three tertiary care centers and a population of deceased patients from a single
year, this study provided an answer for the question “Is there a significant relationship between
ABO blood group and lifespan in a hospitalized population?”
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Chapter Four: Results

This chapter contains the results of the data analysis following the analytical plan
described in Chapter 3. First, results of data exploration and cleaning are presented. Next,
descriptive statistics are given followed by the results of the ANCOVA statistical analyses. All
data was collected from a retrospective review of hospital and blood bank information systems
and data analysis was conducted using SPSS 21.0 software.
Data Cleaning and Missing Data Analysis
Missing data. Data collection from the three sites (WFUBMC, VCUMC and UNCH)
yielded a sample of 3316 patients who expired at the sites during the 2010 calendar year. Of the
total sample, 890 (26.8%) patients did not have an ABO blood group on record or their race was
unknown (Table 12). The race groups were classified as: White, Black, Hispanic, Asian, Native
American and Other. All three sites used a group such as “Other” to indicate that the patient was
not one of the five race groups provided. When the race field was left blank, it was classified as
“unknown” during data collection; and the patient was ultimately removed from the data set.
There was a higher percentage of missing patients than the 15% based on the 2004 UNCH data
(N=871) collected for a similar project (Brecher & Hay, 2011). The percentage of missing data
increased with the larger sample size and inclusion of more variables (such as race, gender and
transfusion history) as expected. Removing the patients with missing data from this sample
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Table 12.
Frequency of Missing Data by Site
WFUBMC
ƒ(%)
N= 1494
466 (31.2)

VCUMC
ƒ(%)
N=965
212 (22.0)

UNCH
ƒ(%)
N=857
36 (4.2)

Total Sample
ƒ(%)
N=3316
714 (21.5)

Race

32 (2.1)

8 (0.8)

32 (3.7)

72 (2.2)

ABO Blood Group and Race

0 (0.0)

3 (0.3)

101 (11.8)

104 (3.1)

498 (33.3)

223 (23.1)

169 (19.7)

890 (26.8)

Missing Variable(s)
ABO Blood Group

Total

Note: WFUBMC = Wake Forest University Baptist Medical Center, VCUMC = Virginia Commonwealth
University Medical Center, UNCH = University of North Carolina Hospitals.

reduced the sample size to 2426. Still born infants were excluded from any analysis prior to
missing data analysis.
Minimum and maximum values, mean, and standard deviation of age at the time of death
were inspected for plausibility and determined to be appropriate. With regard to categorical
variables (ABO blood group, race, gender, site, and transfusion history), outliers were identified
by visually inspecting frequency distributions. Based on these analyses, no out-of-range values
or univariate outliers were found.
Normality of Sampling Distributions
As in all ANOVA, it is assumed that the sampling distributions of means are normal
within each group. Without knowledge of population values or production of actual sampling
distributions of means, this assumption cannot be tested. In addition, the central limit theorem
states that any statistic will have a normal or nearly normal distribution if the sample size is large
enough (N>30) (Tabachnick & Fidell, 2007). Positive skewness was observed for the race
variable in this study’s population. However, skewness by itself poses no problem, since the
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assumptions of normality apply to the sampling distribution of means, and not to the raw scores.
In other words, the distribution of the sample means with large samples is normal regardless of
the distribution of the original raw data, as long as the sample size is large. With the large
sample size and use of two-tailed tests, normality of sampling distributions of means is
anticipated (Tabachnick & Fidell, 2007).
Linearity. The ANCOVA model assumes a linear relationship between each CV and
the DV as well as among pairs of CVs. Inspection of bivariate plots indicates no suggestion of
nonlinearity between each of the CVs (race, gender, site, transfusion history) and the DV (age at
the time of death). However, there is no need to check for linearity with gender or transfusion
history because variables with two levels have only linear relationships with other variables
(Tabachnick & Fidell, 2007).
Homogeneity of variance. It is assumed in ANCOVA that the variance of DV scores
within each cell is a separate estimate of the same population variance. In ANCOVA the
covariances are also evaluated for homogeneity of variance. The probability associated with
Levene’s test for equality of variances [F(3, 2422) = 2.490, p=0.059] is greater than alpha for
diagnostic tests, 0.01 (Tabachnick & Fidell, 2007) . Therefore, the assumption of equal
variances is satisfied.
Homogeneity of regression. Adjustment of scores in ANCOVA is made on the basis of
an average within-cell regression coefficient. The slope of the regression between the DV and
CV(s) within each cell is assumed to be an estimate of the same population regression
coefficient, that is, that the slopes are equal for all cells. Therefore, the assumption of
homogeneity of regression presumes that the CV-DV relationship is the same for all
combinations of the IVs. Heterogeneity of regression implies that there is a different DV-CV(s)
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slope in some cells of the design, or, that there is an interaction between IV(s) and CV(s). When
the assumption of homogeneity of regression is not met, ANCOVA cannot proceed because the
interpretation changes when the values of the CV differ (Tabachnick & Fidell, 2007). The
assumption of homogeneity of regression is tested as an interaction that includes the CVs and the
IV. If it is found to be statistically significant, the assumption is violated. The interactions of
this model were not statistically significant at α = 0.05 and the assumption of homogeneous
regression slopes was satisfied (Table 13).
Table 13.
Evaluation of Homogeneity of Regression
Interaction

df

Error

F

p

ABO*Race

3

2418

1.190

0.312

ABO*Gender

3

2418

0.200

0.896

ABO*Transfusion History

3

2418

1.630

0.180

ABO*Site

3

2418

2.099

0.098

Reliability of covariates. It is assumed in ANCOVA that CVs are measured without
error; the CVs are reliable (Tabachnick & Fidell, 2007). In this study, all data for all variables
were extracted from the medical record rather than self-report. In the case of variables such as
gender and race, the assumption of reliability can usually be justified. It is assumed that people
are reasonably consistent in report of their own gender and race and that high reliability is likely
(Tabachnick & Fidell, 2007). Additionally, as medical records are the official record for a health
care event, the ABO blood group and transfusion history data can be used with sufficient
confidence. Therefore, no adjustment in this ANCOVA was made for unreliability of CVs.
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Results of evaluation of the assumptions of normality of sampling distributions, linearity,
homogeneity of variance, homogeneity of regression and reliability of covariates were
satisfactory. Additionally, no outliers were present.
Descriptive Statistics and Data Exploration
Characteristics of the ABO blood group distributions within the sample are provided in
Tables 14-17 and Figure 6. They are tabulated by race, gender, site and transfusion history. The
data presented have been adjusted for missing values as described previously. This resulted in a
total sample size of 2426 from three sites: WFBMC (N=996), VCUMC (N=742), and UNCH
(N=688). The sample was 56.3% male, 63.4% White, 31.0% Black and 2.1% Hispanic (Tables
14-15). Sixty-one percent of the sample had been transfused with red blood cells within one year
of death (Table 16). WFUBMC patients made up the largest percentage of this group at 41.0%,
followed by VCUMC (30.6%) and UNCH (28.4%) (Table 17). Lifespan, as measured by age at
the time of death, ranged from 0 to 110 with a mean age of 58.7 years (Figure 7).
The racial distribution of the patients differed among the three sites with WFUBMC
having the greatest number of White patients (77.2%) and VCUMC having the least number of
White patients (47.8%) (Table 18). Conversely, WFUBMC had the least number of Black
patients (20.0%) and VCUMC had the greatest number of Black patients (49.1%). UNCH had
the greatest number of Hispanic (4.8%) and Asian (1.2%) patients as well as those classified as
Other (5.4%).
In order to examine the length of life of those with differing ABO blood groups, it is
necessary first to consider the distribution of the ABO blood groups within the study population.
Cumulative frequencies of ABO blood group for the total sample across the three sites were
compared to the known statistics for the general population (Table 3) (Garratty, Glynn, &
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Table 14.
ABO Blood Group Distribution by Gender
Gender
ABO
O

Male
N(%)
614 (45.0)

Female
N(%)
517 (48.7)

A

518 (37.9)

375 (35.3)

B

181 (13.3)

131 (12.4)

AB

52 (3.8)

38 (3.6)

Total

1365 (56.3)

1061 (43.7)

Table 15.
ABO Blood Group Distribution by Race

White
N(%)
690
(44.9)

Black
N(%)
359
(47.7)

Hispanic
N(%)
37
(71.2)

Asian
N(%)
7
(53.8)

Native
American
N(%)
5
(50.0)

A

667
(43.4)

192
(25.5)

10
(19.2)

3
(23.1)

4
(40.0)

17
(27.9)

893
(36.8)

B

131
(8.5)

167
(22.2)

3
(5.8)

3
(23.1)

1
(10.0)

7
(11.5)

312
(12.9)

AB

49
(3.2)

35
(4.6)

2
(3.8)

0
(0.0)

0
(0.0)

4
(6.5)

90
(3.7)

Total

1537
(63.4)

753
(31.0)

52
(2.1)

13
(0.5)

10
(0.4)

61
(2.5)

2426
(100.0)

ABO
O
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Other
N(%)
33
(54.1)

Total
N(%)
1131
(46.6)

Table 16.
ABO Blood Group Distribution by Transfusion History

ABO
O

Transfused
N(%)
689 (46.5)

Not Transfused
N(%)
442 (46.8)

A

548 (37.0)

345 (36.5)

B

192 (13.0)

120 (12.7)

AB

53 (3.6)

37 (3.9)

Total

1482 (61.1)

944 (38.9)

Table 17.
ABO Blood Group Distribution by Site

ABO
O

WFUBMC
N(%)
460 (46.2)

VCUMC
N(%)
354 (47.7)

UNCH
N(%)
317 (46.1)

Total
N(%)
1131 (46.6)

A

379 (38.1)

252 (34.0)

262 (38.1)

893 (36.8)

B

119 (11.9)

107 (14.4)

86 (12.5)

312 (12.9)

AB

38 (3.8)

29 (3.9)

23 (3.3)

90 (3.7)

Total

996 (41.0)

742 (30.6)

688 (28.4)

2426 (100.0)

Note: WFUBMC = Wake Forest University Baptist Medical Center, VCUMC = Virginia Commonwealth
University Medical Center, UNCH = University of North Carolina Hospitals.
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Figure 6. ABO Blood Group Distribution by Race

Figure 7. Age at the Time of Death
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Group AB

Table 18.
Racial Distribution by Site

Race
White

WFUBMC
N(%)
769 (77.2)

VCUMC
N(%)
355 (47.8)

UNCH
N(%)
413 (60.0)

Total
N(%)
1537 (63.4)

Black

199 (20.0)

364 (49.1)

190 (27.6)

753 (31.0)

Hispanic

19 (1.9)

0 (0.0)

33 (4.8)

52 (2.1)

Asian

4 (0.04)

1 (0.1)

8 (1.2)

13 (0.5)

Native American

2 (0.2)

1 (0.1)

7 (1.0)

10 (0.4)

Other

3 (0.3)

21 (2.8)

37 (5.4)

61 (2.5)

Total

996 (41.0)

742 (30.6)

688 (28.4)

2426 (100.0)

Note: WFUBMC = Wake Forest University Baptist Medical Center, VCUMC = Virginia Commonwealth
University Medical Center, UNCH = University of North Carolina Hospitals.

McEntire, 2004). The 2426 hospitalized patients included in the study yielded a phenotypic
distribution of ABO blood groups similar to the known frequencies for the United States
population. Differences within the Hispanic and Asian races were noted. In both of these race
groups, the study population had a higher prevalence of group O (14.7% and 14.0%,
respectively) and a lower prevalence of group A (11.9% and 4.7%, respectively) compared to
national data collected by Garratty, Glynn, and McEntire (2004).
The current study’s population exhibited differences in the frequencies of ABO blood
groups across the races (Table 15, Figure 6). However, regardless of ethnicity, group O made up
the largest proportion of this sample (46.6%) followed by group A (36.8%), group B (12.9 %)
and group AB (3.7%) (Table 15). The Hispanic population had the highest prevalence of group
O (71.2%) compared to the other races and the total sample (Table 15, Figure 6). Additionally, a
higher proportion of group B was found in the Black (22.2%) and Asian (23.1%) populations
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when compared to the White population and the overall population values (Table 15, Figure 6).
The AB blood group was not present in the current study’s Asian and Native American
populations.
Calculations of mean age at the time of death revealed differences among the groups of
variables. Group A, White, female, non-transfused patients, and WFUBMC patients had the
longest lifespans, while group AB, Hispanic, male, and transfused patients had shorter lifespans
(Table 19).
Inspection of the distribution of age at the time of death (Figure 7) indicated a bimodal
curve with the first peak in the very youngest patients and the second peak around 58 years of
age. Because of the bimodal distribution and the likely differences in cause of death for these
two populations, the data was divided into two subsamples: younger (patients who died at less
than 10 years of age) and older (patients who died at age 10 or older). The younger subsample
contained 123 patients from all sites, while the older subsample totaled 2303 patients.
Characteristics of the ABO blood group distributions within each subsample are provided in
Tables 20-28 and are tabulated by race, gender, site and transfusion history.
The younger subsample was 53.7% male, 42.3% White, 39.8% Black and 8.1% Hispanic
(Table 20-21). Almost 80% of this group had been transfused with red blood cells within one
year before death (Table 22). Eighty-five (69.1%) patients in this group died before 1 year of
age (Figure 8). Group O made up the largest percentage of this population (52.0%) followed by
group A (36.6%), group B (8.9 %) and group AB (2.4%) (Table 23). Like the larger total
sample, group O made up a larger proportion of the Hispanic population’s ABO distribution
compared to that of the White population (Table 21). UNCH patients made up the largest

101

Table 19.
Mean Age at the Time of Death by ABO, Race, Gender, Site and Transfusion History

Variable
ABO

Race

Gender

Site

Transfusion History

O

Mean Age at Death
(Years)
57.8

N
1131

Standard
Deviation
22.87

A

59.8

893

21.35

B

59.0

312

19.46

AB

56.9

90

20.91

White

62.1

1537

20.64

Black

54.4

753

21.53

Hispanic

36.0

52

23.30

Asian

49.7

13

25.46

Native American

53.0

10

16.11

Other

49.1

61

29.11

Male

58.1

1365

21.22

Female

59.4

1061

22.60

WFUBMC

62.4

995

20.49

VCUMC

56.1

742

21.02

UNCH

56.1

688

23.77

Transfused

56.2

1482

22.65

Not Transfused

62.6

944

19.88

Note: WFUBMC = Wake Forest University Baptist Medical Center, VCUMC = Virginia Commonwealth
University Medical Center, UNCH = University of North Carolina Hospitals.
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Table 20.
ABO Blood Group Distribution of Younger Patients by Gender
Gender
ABO
O

Male
N(%)
33 (50.0)

Female
N(%)
31 (54.4)

A

29 (43.9)

16 (28.1)

B

3 (4.6)

8 (14.0)

AB

1 (1.5)

2 (3.5)

Total

66 (53.7)

57 (46.3)

Table 21.
ABO Blood Group Distribution of Younger Patients by Race

ABO
O

White
N(%)
24 (46.2)

Black
N(%)
25 (51.0)

Hispanic
N(%)
6 (60.0)

Asian
N(%)
2 (100.0)

Native
American
N(%)
0 (0.0)

A

22 (42.3)

18 (36.7)

3 (30.0)

0 (0.0)

0 (0.0)

2 (20.0)

B

5 (9.6)

5 (10.2)

0 (0.0)

0 (0.0)

0 (0.0)

1 (10.0)

AB

1 (1.9)

1 (2.0)

1 (10.0)

0 (0.0)

0 (0.0)

0 (0.0)

Total

52 (42.3)

49 (39.8)

10 (8.1)

2 (1.6)

0 (0.0)

10 (8.1)
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Other
N(%)
7 (70.0)

Table 22.
ABO Blood Group Distribution of Younger Patients by Transfusion History

ABO
O

Transfused
N(%)
51 (52.0)

Not Transfused
N(%)
13 (52.0)

A

37 (37.8)

8 (32.0)

B

8 (8.2)

3 (12.0)

AB

2 (2.0)

1 (4.0)

Total

98 (79.7)

25 (20.3)

Table 23.
ABO Blood Group Distribution of Younger Patients by Site

ABO
O

WFUBMC
N(%)
20 (54.1)

VCUMC
N(%)
18 (51.4)

UNCH
N(%)
26 (51.0)

Total
N(%)
64 (52.0)

A

15 (40.5)

13 (37.1)

17 (33.3)

45 (36.6)

B

2 (5.4)

4 (11.4)

5 (9.8)

11 (8.9)

AB

0 (0.0)

0 (0.0)

3 (5.9)

3 (2.4)

Total

37 (30.1)

35 (28.4)

51 (41.5)

123 (100.0)

Note: WFUBMC = Wake Forest University Baptist Medical Center, VCUMC = Virginia Commonwealth
University Medical Center, UNCH = University of North Carolina Hospitals.
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Table 24.
ABO Blood Group Distribution of Older Patients by Gender
Gender
ABO
O

Male
N(%)
581 (44.7)

Female
N(%)
486 (48.4)

A

489 (37.6)

359 (35.8)

B

178 (13.7)

123 (12.2)

AB

51 (3.9)

36 (3.6)

Total

1299 (56.4)

1004 (43.6)

Table 25.
ABO Blood Group Distribution of Older Patients by Race

ABO
O

White
N(%)
666 (44.9)

Black
N(%)
334 (47.4)

Hispanic
N(%)
31 (73.8)

Asian
N(%)
5 (45.4)

Native
American
N(%)
5 (50.0)

Other
N(%)
26 (51.0)

A

645 (43.4)

174 (24.7)

7 (16.7)

3 (27.3)

4 (40.0)

15 (29.4)

B

126 (8.5)

162 (23.0)

3 (7.1)

3 (27.3)

1 (10.0)

6 (11.8)

AB

48 (3.2)

34 (4.8)

1 (2.4)

0 (0.0)

0 (0.0)

4 (7.8)

704 (30.6)

42 (1.8)

11 (0.5)

10 (0.4)

51 (2.2)

Total 1485 (64.5)
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Table 26.
ABO Blood Group Distribution of Older Patients by Transfusion History

ABO
O

Transfused
N(%)
638 (46.1)

Not Transfused
N(%)
429 (46.7)

A

511 (36.9)

337 (36.7)

B

184 (13.3)

117 (12.7)

AB

51 (3.7)

36 (3.9)

Total

1384 (60.1)

919 (39.9)

Table 27.
ABO Blood Group Distribution of Older Patients by Site

ABO
O

WFUBMC
N(%)
440 (45.9)

VCUMC
N(%)
336 (47.5)

UNCH
N(%)
291 (45.7)

Total
N(%)
1067 (46.3)

A

364 (38.0)

239 (33.8)

245 (38.5)

848 (36.8)

B

117 (12.2)

103 (14.6)

81 (12.7)

301 (13.1)

AB

38 (3.9)

29 (4.1)

20 (3.1)

87 (3.8)

Total

959 (41.6)

707 (30.7)

637 (27.7)

2303 (100.0)
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Table 28.
Mean Age at the Time of Death of Younger Patients by ABO, Race, Gender, Site and Transfusion
History

Variable
ABO

Race

O

Mean Age at Death
(Years)
1.0

N
64

Standard
Deviation
1.81

A

0.7

45

1.76

B

0.8

11

1.83

AB

1.7

3

2.89

White

0.7

52

1.46

Black

0.7

49

1.90

Hispanic

2.1

10

2.18

Asian

1.5

2

2.12

-

0

-

Other

1.7

10

2.16

Male

0.9

66

1.80

Female

0.9

57

1.82

WFUBMC

0.8

37

1.67

VCUMC

1.0

35

2.06

UNCH

1.0

51

1.74

Transfused

0.7

98

1.63

Not Transfused

1.6

25

2.27

Native American

Gender

Site

Transfusion History

Note: WFUBMC = Wake Forest University Baptist Medical Center, VCUMC = Virginia Commonwealth
University Medical Center, UNCH = University of North Carolina Hospitals.
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Figure 8. Age at the Time of Death of Younger Patients
percentage of this group at 41.5%, followed by WFUBMC (30.1%) and VCUMC (28.4%) (Table
23).
The older subsample was 56.4% male, 64.5% White, 30.6% Black and 1.8% Hispanic
(Table 24-25). A smaller percentage (60.1%) of this group had been transfused compared to the
the younger subsample (Table 22, 26). Group O made up the largest percentage of this sample at
46.3% followed by group A (36.8%), group B (13.1 %) and group AB (3.8%) (Table 27). As
seen in the total sample and the younger subsample, group O made up a larger proportion of the
Hispanic population compared to that of the White population (Table 25, Figure 9).
Additionally, the Black and Asian populations had a higher percentage of Group B patients
compared to the White population. WFUBMC patients made up the largest percentage of this
group at 41.6%, followed by VCUMC (30.7%) and UNCH (27.7%) (Table 27). The greatest
number of patients in this group died in their sixth decade of life, with a mean age at the time of
death of 61.8 years (Figure 10).
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Figure 9. ABO Blood Group Distribution of Older Patients by Race

Figure 10. Age at the Time of Death of Older Patients
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When comparing the demographics of the two subsamples, the gender distribution
appears very similar. However, compared to the older subsample, the younger subsample
contained fewer Whites, and more Blacks, Hispanics and Other. The younger subsample had
been transfused more (79.7%) compared to the older subsample (60.1%). The older subsample
consisted of a higher percentage of patients from WFUBMC (41.6%), whereas the younger
subsample’s highest frequency group was from UNCH (41.5%). When compared to the
younger subsample, the older subsample had a smaller frequency of group O (46.3% vs. 52.0%)
and a larger frequency of group B (13.1% vs. 8.9%).
The mean age at the time of death was calculated for both subsamples and by race,
gender, site and transfusion history (Tables 28-29, Figures 11-20). In the younger subsample,
lifespan was longest for group AB, Hispanic and those patients not transfused. The group AB
patients represented only 2.4% of the younger subsample and all were hospitalized at UNCH. In
the older subsample, lifespan was longest for group A, White, Female, not transfused and
patients at WFUBMC. The pattern seen in the older subsample resembled that of the total
sample (Table 19).
Multivariate Analysis
Initially, a one-way analysis of variance (ANOVA) was performed to determine if age at
the time of death (DV) differed by ABO blood group (IV) without adjustment for CVs. The IV
included the four ABO blood groups: O, A, B, and AB. The effect of ABO blood group on age
at the time of death was not statistically significant, F (3, 2422) = 1.625, p = 0.182 (Table 30).
The average amount of variation between the ABO groups (MSeffect = 774.420) was greater than
that within the groups (MSerror = 476.616), which lead to an F-ratio greater than 1.
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Table 29.
Mean Age at the Time of Death of Older Patients by ABO, Race, Gender, Site and Transfusion
History

Variable
ABO

Race

Gender

Site

Transfusion History

O

Mean Age at Death
(Years)
61.3

N
1067

Standard
Deviation
18.68

A

63.0

848

16.86

B

61.1

301

16.24

AB

58.8

87

18.50

White

64.2

1485

17.44

Black

58.1

704

16.77

Hispanic

44.0

42

18.10

Asian

58.5

11

15.12

Native American

53.0

10

16.11

Other

58.4

51

21.86

Male

61.1

1299

17.27

Female

62.7

1004

18.28

WFUBMC

64.8

959

16.85

VCUMC

58.8

707

17.47

UNCH

60.5

637

18.63

Transfused

60.1

1384

17.78

Not Transfused

64.3

919

17.36

Note: WFUBMC = Wake Forest University Baptist Medical Center, VCUMC = Virginia Commonwealth
University Medical Center, UNCH = University of North Carolina Hospitals.
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Figure 11. Mean Age at Death of Younger Patients by ABO Blood Group
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Figure 12. Mean Age at Death of Younger Patients by Race

112

3.0
2.5

Years

2.0
1.5
1.0
0.5

0.0
Male

Female
Gender

Figure 13. Mean Age at Death of Younger Patients by Gender
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Figure 14. Mean Age at Death of Younger Patients by Site
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Figure 15. Mean Age at Death of Younger Patients by Transfusion History
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Figure 16. Mean Age at Death of Older Patients by ABO Blood Group
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Figure 17. Mean Age at Death of Older Patients by Race
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Figure 18. Mean Age at Death of Older Patients by Gender

115

70.0
60.0

Years

50.0
40.0
30.0
20.0
10.0
0.0
WFUBMC

VCUMC

UNCH

Site

Figure 19. Mean Age at Death of Older Patients by Site
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Figure 20. Mean Age at Death of Older Patients by Transfusion History
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Table 30.
Analysis of Variance of ABO Blood in the Total Sample
Source
ABO

SS
2323.260

df
3

MS
774.420

Error

1154364.653

2422

476.616

Total

9512152.000

2426

F
1.625

p
0.182

Next, the CVs (race, gender, site and transfusion history) were entered into the model and
ANCOVA was performed on age at the time of death for the total sample and separately for the
two subsamples (younger and older). An alpha level of 0.05 was used for all statistical tests.
Analysis of the total sample. After adjustment by covariates, age at the time of death
did not vary significantly with ABO blood group, F (3, 2418) = 0.954, p = 0.413 (Table 31).
When covariates were added into the analysis, the average amount of variation between the ABO
groups (MSeffect = 425.399) was less as was the variation within the groups (MSerror = 445.691).
Covariates are included in the analysis with the expectation that they will reduce MSerror ,
increase the calculated F statistic and reduce the p value so that the null hypothesis can be
rejected. However, the effect here was not enough to show statistical significance for the effect
of ABO blood group on lifespan. Three CVs (race, transfusion history and site) significantly
predicted age at the time of death with significance values less than 0.05. Race accounted for the
most variation accounted for by the model (SS = 33993.468, partial η2 = 0.031).
Analysis of younger subsample. Similar to the total sample, age at the time of death of
the younger subsample did not vary significantly with ABO blood group after adjustment by
covariates, F (3, 115) = 0.185, p = 0.907 (Table 32). In this analysis the relationship between
transfusion and age at time of death approached statistical significance, but only one CV (race)
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Table 31.
Analysis of Covariance of ABO Blood Group in the Total Sample
Source
Gender

SS
1078.502

df
1

MS
1078.502

F
2.420

p
0.120

Race

33993.468

1

33993.468

76.271

0.000

Transfusion History

22018.769

1

22018.769

49.404

0.000

Site

8586.484

1

8586.484

19.266

0.000

ABO

1276.197

3

425.399

0.954

0.413

Error

1077680.202

2418

445.691

Total

9512152.000

2426

Table 32.
Analysis of Covariance of ABO Blood Group in the Younger Subsample
Source
Gender

SS
0.385

df
1

MS
0.385

F
0.121

p
0.728

Race

13.757

1

13.757

4.341

0.039

Transfusion History

11.502

1

11.502

3.629

0.059

Site

0.268

1

0.268

0.084

0.772

ABO

1.756

3

0.585

0.185

0.907

Error

364.464

115

3.169

Total

501.000
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significantly predicted age at the time of death with a significance value less than 0.05. Race
accounted for the most variation accounted for by the model (SS = 13.757, partial η2 = 0.039).
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Analysis of older subsample. After adjustment by covariates, age at the time of death of
the older subsample did not vary significantly with ABO blood group, F (3, 2295) = 1.590, p =
0.190 (Table 33). In this analysis all four CVs significantly predicted age at the time of death
with a significance value less than 0.05. Similar to the younger subsample, race contributed the
most variation accounted for by the model (SS = 12226.434, partial η2 = 0.017).
Table 33.
Analysis of Covariance of ABO Blood Group in the Older Subsample
Source
Gender

SS
1574.406

df
1

MS
1574.406

F
5.242

p
0.022

Race

12226.434

1

12226.434

40.706

0.000

Transfusion History

9023.832

1

9023.832

30.043

0.000

Site

4603.919

1

4603.919

15.328

0.000

ABO

1432.684

3

477.561

1.590

0.190

Error

689324.195

2295

300.359

Total

9511651.000

2303

Comparison with UNCH 2004 pilot data. Similar data from UNCH was collected for a
previous study (Brecher & Hay, 2011) and also used in a pilot analysis for this project. Like the
2010 sample, the 2004 UNCH sample (N=771) resulted in overall ABO frequencies similar to
the general population (Table 7) and a bimodal distribution of age at the time of death (Figure 2).
The 2004 sample consisted of 404 (52.4%) males and 367 (47.6%) females and the majority of
the population had been transfused (76.1%). The racial composition was White (62.6%), Black
(31.4%), Hispanic (3.0%), Asian (0.6%), Native American (0.8%) and unknown (1.6%). The
estimated marginal mean age at the time of death was lowest for the group B patients at 48.0
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years and highest for group AB at 62.5 years (Figure 3). Although this could be explained by a
higher prevalence of group B Black persons, ANCOVA resulted in a statistically significant
difference, F(3, 763), p=0.018, in the age at the time of death among the ABO blood groups
when controlling for race, gender and transfusion history.
Because the results of this 2010 sample disagreed with those of the 2004 pilot data
collected at UNCH, the 2010 UNCH patients (N= 688) were extracted from the total 2010
sample and differences in variables were explored and analyzed using Chi Square analysis
(Table 34). The frequencies of ABO blood groups were similar with the 2010 sample having a
slightly higher proportion of group A patients and a slightly lower proportion of group O
patients. The gender distributions were also very similar. Any differences in ABO blood group
or gender frequencies were not statistically significant. However, the results indicated that the
racial composition of the two samples was statistically different, 2(5, N=1459) = 22.39,
p<0.001. The 2004 UNCH sample contained more Black, and less Hispanic and Asian patients
than the 2010 UNCH sample. Further, a higher proportion of patients in the 2004 sample was
transfused (76.1% vs. 64.8%); this difference was also statistically significant, 2(1, N=1459) =
22.49, p<0.001.
Given that the 2004 UNCH data provided evidence of a statistical difference in lifespan
among the ABO blood groups, the frequency of variables among ABO blood groups were further
compared (Table 35-37). The racial composition of the group O patients in the 2004 UNCH
sample differed significantly from the of the group O patients of the 2010 sample [2(5, N=706)
= 26.93, p<0.001], with a two-fold increase in the frequency of Hispanic group O patients and
decreased frequency of White Group O patients. The 2004 UNCH pilot study suggested that
group B was associated with a shorter lifespan compared to the other ABO blood groups. A

120

Table 34.
Comparison of 2004 and 2010 UNCH Distributions of ABO, Race, Gender and Transfusion
History
2004
N(%)
389 (50.5%)

2010
N(%)
317 (46.1%)

A

264

(34.2%)

262

(38.1%)

B

92

(11.9%)

86

(12.5%)

AB

26

(3.4%)

23

(3.3%)

White

483

(62.6%)

413

(60.0%)

Black

242

(31.4%)

190

(27.6%)

Hispanic

23

(3.0%)

33

(4.8%)

Asian

5

(0.6%)

8

(1.2%)

Native
American

6

(0.8%)

7

(1.0%)

Other

12

(1.6%)

37

(5.4%)

Male

404

(52.4%)

363

(52.8%)

Female

367

(47.6%)

325

(47.2%)

Transfusion Transfused

587

(76.1%)

446

(64.8%)

History

184

(23.9%)

242

(35.2%)

ABO

Race

Gender

Variable
O

Not
Transfused

Note: UNCH = University of North Carolina Hospitals.
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2
3.02

df
3

p
0.388

22.39

5

0.000

0.02

1

0.890

22.49

1

0.000

Table 35.
Comparison of ABO Distribution among Racial Groups in 2004 and 2010 UNCH Data

ABO
O

White
65.8/56.2

Race
Frequency (%) 2004/2010
Native
Black
American Hispanic Asian
28.8/27.8
0.8/1.3
3.3/6.9 0.5/0.9

A

66.7/72.1

28.0/21.0

0.8/1.1

2.3/2.3

1.1/0.8

1.1/2.7

5.25

5

0.386

B

39.1/40.7

53.3/46.5

0.0/0.0

3.3/3.5

0.0/3.5

4.3/5.8

3.84

4

0.428

AB

57.7/47.8

26.9/30.4

3.8/0.0

3.8/8.7

0.0/0.0

7.7/13.0

1.97

4

0.741

Other
0.8/6.9

2
26.93

df
5

p
0.000

Note: UNCH = University of North Carolina Hospitals.

Table 36.
Comparison of ABO Distribution by Gender in 2004 and 2010 UNCH Data
Gender
Frequency (%) 2004/2010
ABO
O

Male
51.9/49.8

Female
48.1/50.2

2
0.30

df
1

p
0.581

A

53.8/54.2

46.2/45.8

0.01

1

0.925

B

47.8/57.0

52.2/43.0

1.49

1

0.222

AB

61.5/60.9

38.5/39.1

0.00

1

0.962

Note: UNCH = University of North Carolina Hospitals.
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Table 37.
Comparison of ABO Distribution by Transfusion History in 2004 and 2010 UNCH Data
Transfusion History
Frequency (%) 2004/2010
2
df
14.64 1

p
0.000

24.2/32.1

3.58

1

0.058

78.3/61.6

21.7/38.4

5.88

1

0.015

65.4/56.5

34.6/43.5

0.40

1

0.525

ABO
O

Transfused
76.9/63.7

Not Transfused
23.1/36.3

A

75.4/67.9

B
AB

Note: UNCH = University of North Carolina Hospitals.

closer look at group B reveals a higher frequency of Black group B patients in 2004 and a higher
rate of transfusion in the group B patients in 2004 compared to the group B patients in 2010.
However, only the difference in transfusion rate between the two samples was found to be
statistically significant for group B patients, 2(1, N=178) = 5.88, p=0.015. In blood group O
patients, the transfusion rates were also statistically different and approached statistical
significance for the group A patients. There were no statistical differences seen for gender
distributions among the ABO blood groups. When mean age at death was compared among the
ABO blood groups and between the 2004 and 2010 UNCH samples, a striking difference was
seen in the lifespan of the group B patients (Table 38). The mean age at the time of death was
11.9 years longer in the 2010 group B patients, and this difference was statistically significant,
t(176) = -3.373, p = 0.001. The differences in mean age at death between the 2004 and 2010
samples were not statistically significant for any other ABO blood group.
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Table 38.
Comparison of 2004 and 2010 UNCH Mean Age at the Time of Death by ABO

ABO
O

2004
Mean Age
at Death
(Years)
N
52.9
389

SD
25.76

2010
Mean Age
at Death
(Years)
N
55.0
317

SD
24.83

t
-1.131

df
704

p
0.258

A

55.8

264

23.97

57.4

262

23.15

-0.786

524

0.432

B

46.4

92

26.07

58.3

86

20.46

-3.373

176

0.001

AB

60.3

26

24.58

47.2

23

26.02

1.821

47

0.075

Note: UNCH = University of North Carolina Hospitals, SD = Standard Deviation

Summary
This chapter summarized the results of the study, including data cleaning and missing
data analysis, descriptive statistics, ANCOVA and comparisons of variable frequencies between
populations. In terms of understanding whether ABO blood group is related to lifespan (age at
the time of death), ANCOVA was conducted in an effort to compare age at the time of death
while controlling for CVs (race, gender, transfusion history and site). Because the sample
yielded a bimodal distribution of age at the time of death, the total sample population was
divided into subsamples (death before 10 years of age, and death at 10 years old or later). The
analyses were conducted on all three populations and each generated similar findings. For each
population, the main effect of ABO blood group on lifespan did not reach statistical significance,
while controlling for the CVs. Due to the lack of statistical significance in the main analyses,
adjusted marginal means, standard errors, adjusted cell means, the evaluation of CV effects, and
the evaluation of intercorrelations was not appropriate.
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Because the current study’s results disagreed with a pilot analysis of 2004 UNCH data in
which group B was associated with a shorter lifespan, the two UNCH populations (2004 and
2010) were compared and analyzed. Interesting differences in racial composition and
transfusion rates were noted. In particular, the mean age at the time of death for group B patients
differed statistically between the two years of data collection. Interpretation of overall results
and discordant findings will be reviewed in the next chapter.

125

Chapter Five: Discussion

The primary aim of this study was to determine if a relationship exists between ABO
blood groups and lifespan in a hospitalized population in the Southeastern United States while
controlling for race, gender, hospital site and history of RBC transfusion within a year of death.
This chapter provides a review of the study’s central findings, a discussion of the conclusions
that can be drawn from the results and suggestions for the overall understanding of the
relationship of ABO blood group to lifespan. It considers how these results compare to those of
other studies and the pilot analysis. This chapter also indicates limitations of the study and
possible areas for future investigation.
ABO Phenotypic Distributions
In order to examine the length of life of those with differing ABO blood groups, it is
necessary first to consider the distribution and frequencies of the ABO blood groups. Worldwide
and in the United States, group O is the most common, followed by group A, then group B with
group AB as the least common (Cavalli-Sforza et al., 1994; Garratty, Glynn, & McEntire, 2004).
However, the ABO frequencies within populations in the race group’s country of origin where
less racial admixtures occur may differ from these values. It should also be noted that the current
study’s data represent the racial categories designated by patients within the categories available
at the three academic medical centers.
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The current study confirmed the highest percentage of group O is found in the Hispanic
population and that the Black and Asian groups have a higher percentage of group B compared
to the other races. However, compared to the national findings of Garratty and colleagues
(2004), higher frequencies of group O were observed among the Hispanic and Asian populations
and 0% of the AB blood group was noted in the Asian and Native American samples. The ABO
phenotype distributions between genders (Table 14), based on transfusion history (Table 16) and
among the three sites (Table 17) demonstrated patterns similar to the overall population
frequencies for the United States.
It is important to note that the present study provides frequencies of the ABO blood
groups from two states in the southeastern United States (Virginia and North Carolina) while the
United States data reported by Garratty and colleagues (2004) represents national frequencies
using a much larger sample (N=3,086,215). Additionally, the sampling method and timeframe
of data collection differed. While the present study represents one year (2010) of data collection,
the United States data was collected over a 10-year period (1991-2000) (Garratty, Glynn, &
McEntire, 2004). Timeframe could account for some variability; the difference in time between
the two samples is at least 10 years. Additionally, the United States data represents healthy
blood donors rather than the hospitalized patients used in the present study. Based on the
multitude of reports that link ABO blood group to disease, it is plausible that the cause of death
which placed the patients in the present study contributed to the different frequencies of ABO
phenotypes in the study population. However, the results of this study provide no evidence of a
relationship between ABO groups and lifespan.
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Lifespan
Because the primary outcome of this research endeavor was as at the time of death or
lifespan, it is important to consider the life expectancy of the pertinent population and how it
may differ when other risk factors (such as gender or race) are included. The National Center for
Health Statistics provides data on life expectancy in the United States by gender and for White
and Black populations (Table 9). For example, life expectancy at birth has shown a disparity
among race with 76 years for White males compared to 70 years for Black males and 81 years
for White females compared to 76 years for Black females. (National Center on Health Statistics,
2007).
The age at the time of death for the study population ranged from 0 to 110 years with a
mean age at death of 58.7 years (Figure 7). When the youngest subsample of patients was
removed from the sample (less than 10 years old), the mean age at death increased to 61.8 years
(Figure 10). This may more accurately represent the population relevant to the study’s primary
question as the youngest patients likely died from different diseases than those reported to have
an association with ABO blood group. Since most of the diseases which have been associated
with the ABO blood groups exert their morbidity and mortality relatively late in life, this seems
reasonable. With life expectancy for the United States population reported to be 77.8 years
(National Center on Health Statistics, 2007), it is clear that the mean age at death of the studied
hospitalized population is much less. It is likely that this reflects poorer health of this population
and their probable circumstance for being hospitalized at death. In a pattern similar to the
reported national life expectancies, the study population also revealed shorter lifespans for Black
and male individuals (Table 9, 19). WFUBMC had the highest mean age at death (62.4 years)
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which may be related to a lower percentage of Black patients compared to the other sites (Table
18, 19).
Transfusion and lifespan. History of RBC transfusion within a year of death was
included as a variable in the present study because the scientific literature provides robust
evidence that transfusion presents risks beyond infectious disease and incompatibility and is
associated with increased mortality (Kamper-Jorgensen et al., 2008; Kleinman, Marshall,
AuBuchon, & Patton, 2004; Tynell, Norda, Shanwell, & Bjorkman, 2001; Tynall, Norda,
Montgomery, & Bjorkman, 2005; Vamvakas & Taswell, 1994; Vamvakas & Moore, 1997;
Wallis, Wells, & Chapman, 2004; Whyte, 1988). There is a substantial body of evidence
demonstrating strong associations between transfusion and adverse outcomes in a range of
clinical settings, including cardiac surgery and acute coronary syndrome, where transfusion is
administered for reasons other than life threatening bleeding (Gerber, 2008; Marik & Corwin,
2008; Murphy et al., 2007; Reeves & Murphy, 2008; Taylor et al., 2006). Results are consistent
in finding increased mortality among transfused patients (Vamvakas & Taswell, 1994,
Vamvakas & Moore, 1997, Kleinman et al., 2004), and these findings make transfusion history
an important factor to consider when examining lifespan or mortality in any group.
Both the transfused and not transfused patients demonstrated a mean age at death below
the published life expectancies; however, a difference in the mean age at death was observed
between those patients who were transfused and those who were not in this current study (Table
19). The mean lifespan of the transfused patients (56.2 years) was well below life expectancy
(77.8 years). Some of this effect could be related to an increased need for transfusion among
patients with more advanced disease, or patients who are at increased risk of dying from trauma
or surgeries. Although the findings appear to show a shorter lifespan for transfused patients,
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conclusions concerning a causal relationship between RBC transfusion and a shortened lifespan
cannot be drawn from this study or the post-transfusion survival studies conducted to date as the
research so far has been descriptive, not etiologic.
ABO blood group and lifespan. There have been many research endeavors
investigating the associations of ABO blood groups with specific diseases, but fewer have
examined an association of ABO blood groups with overall survival or lifespan. The limited
research reports investigating ABO blood group and lifespan are disparate. While a Tokyo
study of centenarians concluded that group B was associated with longevity (Shimizu et al.,
2004), a United States study revealed conflicting results and suggested that group B was a
marker for a shorter lifespan in their population of hospitalized patients (Brecher & Hay, 2011).
The latter study (confined to a UNCH sample) did not include possible covariates, but the data
was used in a pilot analysis for this project which was adjusted for race, gender, and transfusion
history. This pilot analysis revealed similar findings suggesting a shorter lifespan for group B
patients. Further contrasting findings were reported by Vasto and colleagues (2011) in their
comparison of Sicilian centenarians and controls. The authors concluded that the frequencies of
ABO blood groups in their two groups did not differ. To date, authors have not offered a
biological explanation for their findings except to state that a particular ABO blood group may
contribute to lifespan by some biochemical mechanism that allows that particular blood group
to better survive disease.
This study was undertaken in an effort to examine the relationship of ABO and lifespan
in a larger population while controlling for covariates. The data were analyzed as a whole and as
subsamples of the younger (less than 10 years old at death) and older (greater than or equal to 10
years old at death) populations. In all analyses there was no statistical difference in lifespan
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among the ABO blood groups even when controlling for race, gender, site and transfusion
history. Because the results disagreed with the previous results found in the 2004 UNCH pilot
data, the 2010 UNCH patients were extracted from the present sample and were analyzed
separately. This resulted in the same findings, indicating that lifespan does not differ with ABO
blood group.
Comparison of 2004 and 2010 populations. Although the statistical analysis controlled
for covariates, it is important to note some key differences in the demographics of the 2004 and
2010 UNCH data. The 2004 UNCH sample had a slightly higher proportion of group A patients
and a lower proportion of group O patients, but these differences were not statistically significant
(Table 34). Overall, the 2004 UNCH sample had a higher number of Black patients, a lower
number of Hispanic patients and these differences in the racial composition were statistically
significant. Although the overall frequency of group B in both samples was similar, a higher
percentage of the group B patients in the 2004 sample were Black (53.3% vs. 46.5%) (Table 35).
This difference was not statistically significant. When the racial composition within each ABO
group was compared between 2004 and 2010, statistically significant differences were evident
only for group O which showed a higher frequency of White patients and a smaller frequency of
Hispanic patients in the 2004 sample (Table 35). No differences in gender composition were
significant.
Further examination revealed that the 2004 group O and B patients had a statistically
significant higher rate of transfusion when compared to the 2010 sample (Table 37). The
difference in transfusion rate for the group A patients also approached statistical significance.
The 2004 sample had higher frequencies of patients with traits that are associated with shorter
lifespans (such as race, and transfusion history). Inspection of the mean age at death by ABO
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blood group exposed a dramatically lower lifespan for the group B patients of 2004 compared to
the 2010 (46.4 years vs. 58.3 years) (Table 38). A difference in age at the time of death was
statistically significant in the group B patients only.
While previous research reports (Shimizu et al., 2004; Hong et al., 2006; Brecher & Hay,
2011) and 2004 pilot data from UNCH suggested that ABO blood may be associated with
lifespan, this larger and broader study of hospitalized patients in the Southeastern United States
did not. When compared to the UNCH pilot data, the difference in timeframe (2004 vs. 2010)
should be noted. It is possible that medical practice behaviors, prevalence and type of infectious
diseases, or other effects of timeframe may have influenced the results. For example, transfusion
practice is in transition; and there is robust evidence demonstrating strong associations between
transfusion and adverse outcomes in many clinical settings where transfusion is administered for
reasons other than life threatening bleeding (Gerber, 2008; Marik & Corwin, 2008; Murphy et
al., 2007; Reeves & Murphy, 2008; Taylor et al., 2006). A meta-analysis of the effects of
transfusion thresholds on the use of RBC transfusion and clinical outcomes indicated that
restrictive transfusion strategies were associated with a statistically significant decrease in
hospital mortality (Carson, Carless & Hebert, 2012). Due to these recent findings and because
transfusion practice varies, the AABB (formerly, the American Association of Blood Banks)
published a guideline to provide clinical recommendations about thresholds and other clinical
variables that are appropriate triggers for red blood cell transfusions (Carson, et al., 2012). The
AABB recommended adhering to a restrictive transfusion strategy in stable hospitalized patients
and in patients with preexisting cardiovascular disease. The timing of these findings and
consequential clinical recommendations provide one example of how transfusion practice may
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have been evolving between 2004 and 2010. One can see evidence to support this by comparing
the transfusion rates in the UNCH 2004 (76.1%) and 2010 (61.1%) samples.
It is also possible that the patterns and emergence of infectious diseases changed over the
time period from 2004 until 2010. Cohen (2000) describes how changes in our society,
technology and the microorganisms themselves influence the emergence of new diseases, the reemergence of diseases once contained, and the development of antimicrobial resistance. It is not
possible to point to one particular infectious disease that may have changed in prevalence during
this time, but it is possible to highlight real examples of this phenomenon. For instance, during
2010, West Nile virus disease cases were reported from 40 states and the District of Columbia.
The number of reported West Nile virus neuroinvasive disease cases increased 62% from the
number reported in 2009 (Adams, et al., 2012).
Because the outcome variable is lifespan, an examination of the leading causes of death
in 2004 and 2010 may provide insight on any changes in patterns or prevalence of diseases. The
top four causes of death in all age groups in 2004 were: heart disease (27.2%), malignant
neoplasms (23.1%), stroke (6.3%) and chronic lower respiratory disease (5.1%) (Heron, 2007).
The frequencies were similar in 2010: heart disease (24.2%), malignant neoplasms (23.3%),
chronic lower respiratory disease (5.6%), and stroke (5.2%) (Heron, 2013). Although still
ranked at number one, the burden of heart disease has been decreasing since 1980 and similarly,
deaths due to stroke have also seen a decline over time (Heron, 2013). Significant to the present
study are the differences in cause of death that can be seen across age groups. The leading
causes of infant death (less than 1 year old) in both 2004 and 2010 were congenital
malformations (20.1% and 20.8%, respectively) and disorders related to short gestation and low
birth weight (16.6% and 16.9%). In children aged one to four years old, death due to
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unintentional injury becomes the number one cause, followed by congenital malformations. For
populations 45 years old and over, chronic diseases accounted for more deaths than other causes.
In both 2004 and 2010, cancer was first and heart disease was second for the 45 to 64 year age
group; while for those 65 or older, heart disease was first and cancer was second. These data
support the notion that the younger and older subpopulations of the present study died of
different causes and therefore, should be analyzed separately.
Within this context, all race groups shared seven of the ten leading causes of death, but
exhibited differences in relative disease burden (Heron, 2007; Heron, 2013). For example, heart
disease and cancer were the first and second causes of death for White and Black populations in
2004 and 2010, but cancer was first and heart disease second for the Asian and Hispanic
populations. While overall ABO frequencies were not significantly different between the 2004
and 2010 UNCH study populations, there were differences in the racial composition of the group
O patients between samples. As previously noted, the group O patients of the 2010 sample had
twice the frequency of Hispanic patients and a lesser prevalence of White patients. This may be
relevant to the present study’s findings since there have been many reports linking ABO blood
group with heart disease (Medalie et al., 1971; Garrison et al., 1976; Rosenberg et al., 1983;
Whincup, Cook, Phillips, & Shaper, 1990; Meade et al., 1994; Green, Jarrett, Ruth, Folsom, &
Liu, 1995; Suadicani, Hein, & Gyntelberg, 2000; O'Donnell & Laffan, 2001; Ketch et al., 2008;
Anvari et al., 2009). Although a consensus has not been reached, the most recent reports with
larger sample sizes show an association with group O and heart disease (Suadicani, Hein, &
Gyntelberg, 2000; O'Donnell & Laffan, 2001; Anvari et al., 2009). Variances in cause of death
among age groups and race provide evidence that cause of death could be a confounding variable
in this study and may have contributed to the difference in findings between the 2004 and 2010
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populations. It is clear that there may have been changes in our environment (such as infectious
disease patterns), changes in medical practice (such as transfusion thresholds), or variances in
cause of death that affected outcomes in the 2004 and 2010 samples, but the design of this
project did not allow for direct measurement of these effects.
An important variance to note regarding the 2004 and 2010 data is the method for
extracting the transfusion history. “Transfused” 2004 patients included patients that had any
record of RBC transfusion present in the UNCH blood bank information system at any time. In
contrast, the look back for RBC transfusion for the 2010 patients only included one year prior to
the date of the patient’s death. Limiting the look back to one year was an effort to standardize
the procedure among the three 2010 sites (due to any changes in information systems), but this
difference may have affected the results of the study. It is possible that a further look back
would have resulted in more patients being included in the “transfused” category for the 2010
sample.
There were inherent differences in the 2004 and 2010 UNCH samples that may have
contributed to the discordant results. Dissimilarities in racial distribution and transfusion history
were observed in the data. Although differences were noted for racial composition and
transfusion history, a difference in the outcome variable (lifespan) was observed only for group
B patients. It is possible that the group B patients of the 2004 UNCH sample had other
unmeasured characteristics or more severe medical conditions (which required more
transfusions) and put them at greater risk of death. For example, deep vein thrombosis and heart
disease have been associated with group B (Jick, Dinan, Herman, & Rothman, 1978, Koster,
Blann, Briet, Vandenbroucke, & Rosendaal, 1995, Robert et al., 2000, Green, Jarrett, Ruth,
Folsom, & Liu, 1995, Medalie et al., 1971). Because both analyses controlled for race, gender,
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and transfusion history, it appears that the difference in the two data sets is something that was
not measured in this project.
It is also important to examine how the results of this project compare to previously
published studies. The study participants in the research report of ABO blood group and lifespan
(Shimizu et al., 2004; Hong et al., 2006; Vasto et al., 2011) differed from the present study’s
population with regard to geographic location, racial makeup and patient type. It should be
noted that the geographic location and the low number of Asians in the present study (N=13), did
not allow for a direct comparison of results with the investigation of Shimizu and colleagues
(2004). Patients of previous studies were also limited to centenarians or liver transplant
recipients rather than all patients who expired at an academic medical center (Shimizu et al.,
2004; Hong et al., 2006; Vasto et al., 2011). Additionally, the sample from the present study did
not result in a proportion of centenarians (N=3) that could be examined separately. Therefore, it
is difficult to evaluate if these results are in direct contrast to other published findings.
The scientific literature provides a variety of data regarding the relationship of ABO
phenotype with diseases and disorders, as well as overall length of life and survival. Reports of
positive correlations with ABO blood group exist for: infectious disease, heart disease,
pulmonary function, cancer, obesity, length of life, survival, and even behavioral traits (Table 6).
It stands to reason that if a particular blood group provides a protective mechanism against
serious illness, then that blood group should exhibit a longer lifespan. While the overwhelming
majority of reports indicate an association with a particular ABO phenotype, it is important to
note the potential for positive outcome bias. It is possible that studies indicating no association
with ABO phenotype are less likely to be submitted for publication or to be accepted for
publication. Additionally, the protective effect observed for ABO blood group does not
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consistently point to one particular ABO group (Table 5, 6). Depending on the disease
prevalence within a particular population or geographic location, one might predict that a
particular ABO blood group would survive best based on previous reported associations.
Because the current study population differed in geographic location and timeframe from
previously reported studies, it is reasonable to suspect that changes or disparities in disease
predominance in the populations may have contributed to divergent results. Additionally, by
including three academic medical centers and thus, a wider geographic area, the effect of an
association with a particular disease more prevalent in one location could have been diluted out
by the larger sample size and geographic area.
Limitations
While this study is the largest to date to examine the relationship between ABO blood
group and lifespan and provides valuable information, it has some limitations as well. The
primary statistical test used in this analysis, ANCOVA, held theoretical limitations. If a
relationship among ABO blood groups and lifespan had been elucidated, ANCOVA would not
have assured that changes in lifespan were caused by ABO blood group. The inference of
causality is a logical and scientific, rather than statistical, problem. Because this project was
nonexperimental, causality is not justified.
There are inherent challenges and constraints when investigating any group of
hospitalized patients and some of these existed with the other published studies in this area of
interest. Specifically, there are limitations with the ability to generalize the results and it should
be noted that the results can only be generalized to “hospitalized” patients. As “hospitalized”
patients, the patients in this study were almost certainly different than the general population.
Further, it is probable that these patients were in poorer health and had more complex medical
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histories than patients who die in more rural hospital settings or assisted living facilities. It is
possible that people who die in non-hospital settings are demographically different than the
sample used for this project. Additionally, care must be taken when generalizing the results to
populations other than those at academic medical centers which provide a large and
disproportionate amount of indigent care and services for the most complicated cases that have
been referred from other sites (Billi, Pai, Rothman, & Spahlinger, 2005; Moy, Valente, Levin, &
Griner, 1996). It is possible that the patients in the sample for this project were older, had more
complex disease processes or a different economic composition. Sampling from populations
dying outside of a medical facility would present some challenges in data collection. It would
likely be impossible to determine the ABO blood group, an accurate transfusion history and
many other patient characteristics for the majority of people who die outside of a healthcare
facility. For these reasons, using tertiary care centers provided the best opportunity to obtain a
diverse sample population and access the data needed.
The mean age at death in the study population is earlier than the published life
expectancy for the United States. This provides some evidence that this hospitalized population
dying at academic medical centers is less healthy than those who die elsewhere. Therefore, it is
possible that the relationship of poorer health and shorter lifespan to ABO blood group cannot be
investigated without considering primary disease state, comorbidities or cause of death. These
potential confounders were not included in the original design due to potential complexity, and
ambiguity of the primary illness and/or cause of death in the medical record. Although it was not
an objective of this study, without information regarding patient illness, it is not possible to tease
out any associations between ABO blood group and disease.
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It should also be noted that 27% of the original study population did not have ABO
and/or race in their medical record and were excluded from the analysis. It is possible that these
patients were different than the overall population. There may be some confounding factor that
precluded obtaining an ABO blood group on these patients such as severity of illness, or
religious affiliation.
While the study was intended to address the Southeastern United States, it represents only
three academic medical centers and two states (Virginia and North Carolina) in the Southeast. In
contrast to most other studies, this research was conducted with the explicit aim to discover
relationships among variables for a specific group of people at one point in time. While
generalizability to Virginia and North Carolina populations is inherent, the use of these results
for other states or other countries is limited. Sampling more academic medical centers across a
broader geographic region would have enhanced generalizability. Given that a previous study of
contradictory results included an Asian population, one might question whether or not there was
a sufficient Asian group within the study population. A very small proportion of the total study
population was Asian (0.5%) and it is not appropriate to compare these findings directly with the
findings of a population in another country. At the very least, differences in the health care
system as well as differences in the presence or prevalence of certain disease patterns, make the
results applicable to the populations of these two states only.
Due to the non-experimental nature of this study, concerns of internal validity must be
explored. For example, the one-year timeframe of the study may have imposed a threat of
history. Although unlikely, changes in the practice patterns of surgeons, new surgical
procedures, changes in the delivery of health services or the availability of services over the year
timeframe may have contaminated the results of the study. Differences in survival could also be
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explained by the use of different transfusion triggers, population specific characteristics,
variation in transfusion policy or differences in standards of medical care between countries,
between hospitals, or over time. However, the threat of instrumentation was not a problem. The
contents of the hospital or blood bank information systems, the format of their databases, and the
usability of the databases were consistent among the three sites and over the study’s timeframe.
Another confounding variable that was not measured was socioeconomic status as it is
related to lifespan and virtually all health outcomes in most countries. Although Blacks, Native
Americans, and Hispanics are disproportionately represented among the more socioeconomically
disadvantaged groups in the United States, racial disparities do not simply reflect differences in
income and the likelihood of poor or fair health are seen within each income group (Robert
Wood Johnson Foundation, 2008). Therefore, it is possible that differences in this variable may
have affected results.
Cognizance of the limitations is important as is realizing the limitations do not invalidate
the utility of the findings. Several peer-reviewed articles have been published using smaller
samples and less adjustment for covariates. This highlights the acceptance by the research
community and the importance of the question. Communicating clearly what was found and not
over generalizing the results is paramount. Even though this research will need to be replicated
in other areas of the United States and other countries, the present project is the largest study to
date in the United States and adds to the existing body of knowledge.
Future Research
Additional research is needed to advance this area of study. Future work should be done
on expanded populations that cover a wider geographic area. Increasing the geographic area to
include more areas of the United States would make the results more generalizable and may
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increase the racial diversity of the sample. In addition, it may be necessary to specifically search
for larger Asian populations or centenarians in order to more appropriately compare results with
the findings of Shimizu and colleagues (2004) and Vasto and colleagues (2011). Data from
previous studies may have been impacted by the use of individuals with advanced ages. Efforts
to measure ABO blood group in persons of increased age could include the use of ambulatory
geriatricians or other home health providers as sources for other aged populations. Because the
older subpopulation in this study contained a wide range of ages at death (10 to 110 years old),
further stratification of this group by decade may elucidate differences in the population in the
oldest age groups. Furthermore, this study indicated that race accounted for much of the
variability in outcome; however, it is possible that the differences due to racial disparities may
decrease after age 65. United States data shows that differences in life expectancy for White and
Black persons at 65 years of age are smaller than differences at birth (11.2 years versus 5.1
years) (U.S. Department of Health and Human Services, n.d.). Therefore, further examination of
the oldest patients in this study (those greater than 65 years old at death), may provide results
less affected by racial differences.
Additionally, future studies that include primary disease or comorbidities may provide
more evidence for a functional role of ABO blood group. Even though the relationship of ABO
blood group with disease or overall lifespan is not fully understood by the scientific community,
the evidence suggesting associations between blood groups and particular diseases or disorders is
expansive (Aird et al., 1953; Albert, 1996; Hein et al., 1998; O'Donnell & Laffan, 2001;
Suadicani et al., 2007). Further, the collection of cause of death data may increase the ability to
link ABO to disease and therefore, earlier death or prolonged survival. Advances in molecular
genetics and cellular biochemistry may help to provide information regarding the structure of
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blood group antigens which could be used in conjunction with epidemiological data to establish a
link with ABO blood groups, disease and overall survival. Furthermore, the investigation of the
biochemical mechanisms responsible for a longer lifespan in a particular blood group would
allow for reflection and suggestions of how genetic inheritance and relative prevalence of ABO
blood groups might be related to environmental factors.
Conclusion
Beginning with Landsteiner’s discovery (1900), our understanding of the ABO blood
group system has grown and scientists have been able to study one of the first human
characteristics proven to be inherited. The ABO blood group antigens also appear to have been
important throughout our evolution because the frequencies of different ABO blood types vary
among different populations (Cavalli-Sforza, Menozzi, & Piazza, 1994), suggesting that a
particular blood type conferred a selection advantage. Because the frequencies of ABO blood
group phenotypes are not equal, it has been suggested that polymorphic genes provide
intraspecies diversity which allows coping with diverse and rapidly evolving pathogens
(Marionneau et al., 2001). The distribution of the four ABO blood groups (A, B, AB and O),
varies in populations throughout the world (Cavalli-Sforza et al., 1994). Because environments
are dynamic, it may be that a gene or trait that hindered survival and reproduction in the past,
might aid in survival and reproduction today. In this way, natural selection and adaptation work
to adjust the prevalence of traits so that they are suited for a particular environment and could
influence frequencies and prevalence of ABO blood groups. Adding support to this theory, some
research reports have shown that specific ABO blood types are associated with increased or
decreased susceptibility to particular diseases (Albert, 1996; Cheng et al., 2005; Hein et al.,

142

1998; Kalayanarooj et al., 2007; Shimazu et al., 2000) and that ABO blood group antigens could
have a physiological role previously unknown.
The primary purpose of this study was to examine the relationship between ABO blood
group and lifespan in a hospitalized population in the Southeastern United States. In order to
examine this relationship, the prevalence of ABO blood groups within the population and mean
lifespan of each ABO blood group was determined. The analyses were adjusted for the effects of
race, gender, transfusion history and site. Throughout this study, knowledge was gained about
the distribution of ABO blood group in the hospitalized population and among race, the lifespan
of those dying in the tertiary care centers, as well as the race, gender and transfusion history
distributions among this population. The findings indicated that ABO blood group distribution
differs among the race groups and lifespan differs most among the race groups. This study’s
sample size is the largest to date to examine this question and provided enough power to detect a
difference in lifespan due to ABO blood group if a difference actually existed. However, the
results showed that ABO blood group was not a predictor for lifespan in a hospitalized
population in the Southeastern United States and that other variables have a stronger influence on
lifespan.
There have been many research endeavors regarding the associations of ABO blood
groups with specific diseases, but fewer have examined an association with ABO blood groups
and overall survival or lifespan. Disparate conclusions concerning a relationship among ABO
blood groups and lifespan supported the need for a larger, more comprehensive study to address
this question. Given the plethora of existing research in the arena of ABO blood groups and
disease correlation, the need for a large scale study to look at its overall influence on lifespan
was important and relevant for healthcare. It is clear that consensus has not been reached at this
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time, but the study of ABO blood groups in relation to disease and lifespan is one of evolutionary
significance and may prove to reflect a functional role of the antigens on RBCs.
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